

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
6 September 2002 (06.09.2002)

PCT

(10) International Publication Number  
**WO 02/068694 A1**

- (51) International Patent Classification<sup>7</sup>: **C12Q 1/68**
- (21) International Application Number: **PCT/US02/05681**
- (22) International Filing Date: 25 February 2002 (25.02.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/271,268 23 February 2001 (23.02.2001) US
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:  
US 60/271,268 (CIP)  
Filed on 23 February 2001 (23.02.2001)
- (71) Applicant (for all designated States except US): **THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE** [US/US]; 111 Market Street, Suite 906, Baltimore, MD 21202 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **GOGGINS, Michael, G.** [US/US]; 4446 Roland Springs Drive, Baltimore, MD 21210 (US). **UEKI, Takashi** [JP/US]; 2-C, Jonathans Path, Sparks, MD 21152 (US).
- (74) Agent: **HAILE, Lisa, A.**; Gray Cary Ware & Freidenrich LLP, Suite 1100, 4365 Executive Drive, San Diego, CA 92121-2133 (US).
- (81) Designated States (*national*): AE, AG, AI, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
- with international search report
  - before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

BEST AVAILABLE COPY

(54) Title: DIFFERENTIALLY METHYLATED SEQUENCES IN PANCREATIC CANCER

(57) Abstract: The present invention provides a method for detecting a cellular proliferative disorder in a subject. The method includes contacting a nucleic acid-containing specimen from the subject with an agent that provides a determination of the methylation state of at least one gene or associated regulatory region of the gene and identifying aberrant methylation of regions of the gene or regulatory region, wherein aberrant methylation is identified as being different when compared to the same regions of the gene or associated regulatory region in a subject not having said cellular proliferative, thereby detecting a cellular proliferative disorder in the subject.

## DIFFERENTIALLY METHYLATED SEQUENCES IN PANCREATIC CANCER

### FIELD OF THE INVENTION

The present invention relates generally to the regulation of gene expression and more specifically to a method of determining the DNA methylation status of CpG sites in a given locus and correlating the methylation status with the presence of a cell proliferative disorder.

### BACKGROUND OF THE INVENTION

DNA methylases transfer methyl groups from the universal methyl donor S-adenosyl methionine to specific sites on the DNA. Several biological functions have been attributed to the methylated bases in DNA. The most established biological function for methylated DNA is the protection of DNA from digestion by cognate  
10 restriction enzymes. The restriction modification phenomenon has, so far, been observed only in bacteria. Mammalian cells, however, possess a different methylase that exclusively methylates cytosine residues that are 5' neighbors of guanine (CpG). This modification of cytosine residues has important regulatory effects on gene expression, especially when involving CpG rich areas, known as CpG islands, located  
15 in the promoter regions of many genes.

Methylation has been shown by several lines of evidence to play a role in gene activity, cell differentiation, tumorigenesis, X-chromosome inactivation, genomic imprinting and other major biological processes (Razin, A., H., and Riggs, R.D. eds. in DNA Methylation Biochemistry and Biological Significance, Springer-Verlag, New  
20 York, 1984). In eukaryotic cells, methylation of cytosine residues that are immediately 5' to a guanosine, occurs predominantly in CG poor regions (Bird, A., Nature, 321:209, 1986). In contrast, CpG islands remain unmethylated in normal cells, except during X-chromosome inactivation (Migeon, et al., supra) and parental specific imprinting (Li, et al., Nature, 366:362, 1993) where methylation of 5'  
25 regulatory regions can lead to transcriptional repression. De novo methylation of the Rb gene has been demonstrated in a small fraction of retinoblastomas (Sakai, et al.,

Am. J. Hum. Genet., 48:880, 1991), and recently, a more detailed analysis of the VHL gene showed aberrant methylation in a subset of sporadic renal cell carcinomas (Herman, et al., Proc. Natl. Acad. Sci., U.S.A., 91:9700, 1994). Expression of a tumor suppressor gene can also be abolished by de novo DNA methylation of a normally  
5 unmethylated CpG island (Issa, et al., Nature Genet., 7:536, 1994; Herman, et al., supra; Merlo, et al., Nature Med., 1:686, 1995; Herman, et al., Cancer Res., 56:722, 1996; Graff, et al., Cancer Res., 55:5195, 1995; Herman, et al., Cancer Res., 55:4525, 1995).

Human cancer cells typically contain somatically altered nucleic acid,  
10 characterized by mutation, amplification, or deletion of critical genes. In addition, the nucleic acid from human cancer cells often displays somatic changes in DNA methylation (E.R. Fearon, et al., Cell, 61:759, 1990; P.A. Jones, et al., Cancer Res., 46:461, 1986; R. Holliday, Science, 238:163, 1987; A. De Bustros, et al., Proc. Natl. Acad. Sci., USA, 85:5693, 1988); P.A. Jones, et al., Adv. Cancer Res., 54:1, 1990;  
15 S.B. Baylin, et al., Cancer Cells, 3:383, 1991; M. Makos, et al., Proc. Natl. Acad. Sci., USA, 89:1929, 1992; N. Ohtani-Fujita, et al., Oncogene, 8:1063, 1993). However, the precise role of abnormal DNA methylation in human tumorigenesis has not been established. Aberrant methylation of normally unmethylated CpG islands has been described as a frequent event in immortalized and transformed cells, and has been  
20 associated with transcriptional inactivation of defined tumor suppressor genes in human cancers. In the development of colorectal cancers (CRC), a series of tumor suppressor genes (TSG) such as APC, p53, DCC and DPC4 are inactivated by mutations and chromosomal deletions. Some of these alterations result from a chromosomal instability phenotype described in a subset of CRC. Recently, an  
25 additional pathway has been shown to be involved in a familial form of CRC, hereditary non-polyposis colorectal cancer. The cancers from these patients show a characteristic mutator phenotype which causes microsatellite instability (MI), and mutations at other gene loci such as TGF- $\beta$ -RII (Markowitz et al., Science, 268(5215):1336-8, 1995) and BAX. This phenotype usually results from mutations in  
30 the mismatch repair (MMR) genes hMSH2 and hMLH1. A subset of sporadic CRC

also show MI, but mutations in MMR genes appear to be less frequent in these tumors.

Another molecular defect described in CRC is CpG island (CGI) methylation. CGIs are short sequences rich in the CpG dinucleotide and can be found in the 5' region of about half of all human genes. Methylation of cytosine within 5' CGIs is associated with loss of gene expression and has been seen in physiological conditions such as X chromosome inactivation and genomic imprinting. Aberrant methylation of CGIs has been detected in genetic diseases such as the fragile-X syndrome, in aging cells and in neoplasia. About half of the tumor suppressor genes which have been shown to be mutated in the germline of patients with familial cancer syndromes have also been shown to be aberrantly methylated in some proportion of sporadic cancers, including Rb, VHL, p16, hMLH1, and BRCA1. TSG methylation in cancer is usually associated with (Antequera, et al., Proc. Natl. Acad. Sci. USA, 90:11995-11999, 1993) lack of gene transcription and (Baylin, et al., Adv. Cancer Res., 72:141-196, 1998) absence of coding region mutation. Thus it has been proposed that CGI methylation serves as an alternative mechanism of gene inactivation in cancer.

The causes and global patterns of CGI methylation in human cancers remain poorly defined. Aging could play a factor in this process because methylation of several CGIs could be detected in an age-related manner in normal colon mucosa as well as in CRC. In addition, aberrant methylation of CGIs has been associated with the MI phenotype in CRC as well as specific carcinogen exposures. However, an understanding of aberrant methylation in CRC has been somewhat limited by the small number of CGIs analyzed to date. In fact, previous studies have suggested that large numbers of CGIs are methylated in immortalized cell lines, and it is not well understood whether this global aberrant methylation is caused by the cell culture conditions or whether they are an integral part of the pathogenesis of cancer.

Most of the methods developed to date for detection of methylated cytosine depend upon cleavage of the phosphodiester bond alongside cytosine residues, using either methylation-sensitive restriction enzymes or reactive chemicals such as

hydrazine which differentiate between cytosine and its 5-methyl derivative. Genomic sequencing protocols which identify a 5-MeC residue in genomic DNA as a site that is not cleaved by any of the Maxam Gilbert sequencing reactions have also been used, but still suffer disadvantages such as the requirement for large amount of genomic DNA and the difficulty in detecting a gap in a sequencing ladder which may contain bands of varying intensity.

Mapping of methylated regions in DNA has relied primarily on Southern hybridization approaches, based on the inability of methylation-sensitive restriction enzymes to cleave sequences which contain one or more methylated CpG sites. This method provides an assessment of the overall methylation status of CpG islands, including some quantitative analysis, but is relatively insensitive and requires large amounts of high molecular weight DNA.

Another method utilizes bisulfite treatment of DNA to convert all unmethylated cytosines to uracil. The altered DNA is amplified and sequenced to show the methylation status of all CpG sites. However, this method is technically difficult, labor intensive and without cloning amplified products, it is less sensitive than Southern analysis, requiring approximately 10% of the alleles to be methylated for detection.

Identification of the earliest genetic changes in tumorigenesis is a major focus in molecular cancer research. Diagnostic approaches based on identification of these changes are likely to allow implementation of early detection strategies and novel therapeutic approaches targeting these early changes might lead to more effective cancer treatment.

About half of all human genes have 5' CpG islands and these islands are usually associated with the 5' regulatory regions of genes (Antequera, et al., Proc. Natl. Acad. Sci. USA 90:11995-11999, 1993). The 5' CpG islands of most nonimprinted genes are thought to remain unmethylated in normal cells but may become methylated during aging or tumorigenesis. Through interactions between

methy CpG binding proteins, histones and histone deacetylase, 5' CpG island methylation can contribute to changes in chromatin that cause transcriptional silencing (Baylin, et al., *Adv. Cancer Res.* 72:141-196, 1998). Promoter methylation is implicated in the transcriptional silencing of tumor suppressor and mismatch repair genes (e.g. p16, Rb, VHL, hMLH1) in many cancers. Although 13 hypermethylated genes and clones in pancreatic cancers were previously identified (Ueki, et al., *Cancer Res.* 60:1835-1839, 2000), there almost certainly are others. Costello et al. have estimated that ~400 genes are aberrantly methylated in cancers and have found evidence for tumor-specific pattern of methylation (Costello, et al., *Nat. Genet.* 24:132-138, 2000). A better description of the pattern of DNA methylation abnormalities in cancer may improve an understanding of the role of DNA methylation in tumorigenesis and identification of differentially methylated CpG islands in cancer may lead to the discovery of novel genes with tumor suppressor properties. Finally, identified genes or loci could be utilized as cancer-specific markers for the early detection of cancer (Belinsky, et al., *Proc. Natl. Acad. Sci. USA* 95:11891-11896, 1998).

Pancreatic cancer is the fourth leading cause of cancer death in men and in women and each year ~28,000 Americans die of the disease (Greenlee, et al., *CA Cancer J. Clin.* 50:7-33, 2000). Frequent genetic changes such as mutational activation of the K-ras oncogene and inactivation of the p16, DPC4, p53, MKK4, STK11, TGFBR2, and TGFBR1 tumor suppressor genes have been described in pancreatic cancer (Goggins, et al., *Ann. Oncol.* 10:4-8, 1999, Rozenblum, et al., *Cancer Res.* 57:1731-1734, 1997). Although multiple tumor suppressor pathways have been shown to play a role in pancreatic carcinogenesis, little is known about the contribution of DNA methylation to inactivation of genes in these pathways. Recently, a novel technique, methylated CpG island amplification (MCA), was developed to enrich for methylated CpG rich sequences. MCA coupled with RDA (MCA/RDA) can recover CpG islands differentially methylated in cancer cells (Toyota, et al., *Cancer Res.* 59:2307-2312, 1997).

### SUMMARY OF THE INVENTION

The present invention is based on the finding that several genes are newly identified as being differentially methylated in cancer. This seminal discovery is useful for cancer screening, risk-assessment, prognosis, minimal-residual disease identification, staging and identification of therapeutic targets. The identification of new genes that are methylated in cancer, aging or diseases associated with aging increases the likelihood of finding genes methylated in a particular cancer; increases the sensitivity and specificity of methylation detection; allows methylation profiling using multiple genes; and allows identification of new targets for therapeutic intervention. The invention also provides a newly identified gene that is a target for hypermethylation in human tumors.

In one embodiment, there are provided methods for detecting a cellular proliferative disorder in a subject. The subject may have or be at risk of having a cellular proliferative disorder. The method of the invention is useful for diagnostic as well as prognostic analyses. One method for detecting a cellular proliferative disorder in a subject includes contacting a nucleic acid-containing specimen from the subject with an agent that provides a determination of the methylation state of at least one gene or associated regulatory region of the gene; and identifying aberrant methylation of regions of the gene or regulatory region, wherein aberrant methylation is identified as being different when compared to the same regions of the gene or associated regulatory region in a subject not having the cellular proliferative, thereby detecting a cellular proliferative disorder in the subject. The method includes multiplexing by utilizing a combination of primers for more than one loci, thereby providing a methylation "profile" for more than one gene or regulatory region.

For the first time, the invention provides methylated forms of genes and/or their associated regulatory sequences referred to herein as MICP1-42. MICP39-42 have no homology to known human sequences. Eleven clones matched human genes (MICP1-11); 10 clones matched human ESTs (MICP12-21); 5 clones matched human

CpG islands (MICP22-26); and 12 clones matched human genome sequences (MICP27-38). (see Table 1 as reference).

Invention methods include determining, in a nucleic acid-containing specimen taken from a subject, the methylation state of a gene or regulatory sequences associated therewith, wherein the expression or non-expression of the gene is associated with the presence of the cellular proliferative disorder, and identifying as having a cellular proliferative disorder a subject that has aberrant methylation of regions of the gene or associated regulatory sequences when compared to the same regions of the gene in a subject not having the cellular proliferative disorder. In one aspect of this embodiment, the methylated regions of the gene and associated regulatory sequences are contained within CpG islands (i.e., CpG rich regions). In particular, the aberrant methylation typically includes hypermethylation as compared with the same regions of the gene or regulatory sequences in a subject not having the cellular proliferative disorder.

Determining the methylation state of the gene includes contacting the nucleic acid-containing specimen with an agent that modifies unmethylated cytosine, amplifying a CpG-containing nucleic acid in the specimen by means of CpG-specific oligonucleotide primers, wherein the oligonucleotide primers distinguish between modified methylated and nonmethylated nucleic acid, and detecting the methylated nucleic acid based on the presence or absence of amplification products produced in said amplifying step. The method includes optionally contacting the amplification products with a methylation sensitive restriction endonuclease. Other methods for determining methylation status of a gene and/or regulatory sequences are well known in the art and are described more fully herein.

In another embodiment of the present invention there is provided a kit useful for the detection of a cellular proliferative disorder in a subject having or at risk for having a cellular proliferative disorder. Invention kits include a carrier means compartmentalized to receive a sample, one or more containers comprising a first container containing a reagent which modifies unmethylated cytosine and a second



container containing primers for amplification of a CpG-containing nucleic acid, wherein the primers distinguish between modified methylated and nonmethylated nucleic acid, and optionally, a third container containing a methylation sensitive restriction endonuclease. In a preferred embodiment, the cell proliferative disorder is  
5 pancreatic carcinoma.

To identify CpG islands differentially methylated in pancreatic adenocarcinoma, methylated CpG island amplification (MCA) was used, coupled with representational difference analysis (MCA/RDA). Clones differentially methylated (termed MICP, methylated in carcinoma of the pancreas) were isolated in a panel of 8  
10 pancreatic cancer cell lines compared to normal pancreas. 95% of these clones were CpG islands and among these clones were 5' CpG islands of several known genes, including Cyclin G and Preproenkephalin (ppENK, encoding [Met5]-enkephalin). Seven of the clones (Cyclin G, ppENK, MICP20, 23, 33, 35 and 36) were not methylated in 14 normal pancreata by MSP while 15 primary pancreatic  
15 adenocarcinomas were methylated in 7%, 87%, 13%, 53%, 33%, 40% and 0% of cases, respectively. Two of the 5 chronic pancreatitis specimens harbored methylation of three (Cyclin G, ppENK and MICP23) and one (ppENK) clones, respectively. There was no identification of methylation of MICP33 and 35 in any normal gastrointestinal tissues tested. Three clones (ppENK, MICP20 and 23) were variably  
20 methylated in normal gastric, duodenal and colonic mucosae. Aberrant methylation of Cyclin G and ppENK in methylated pancreatic cancer cell lines was associated with transcriptional silencing that was reversible with 5-aza-2'-deoxycytidine treatment.

These data indicate that multiple CpG islands undergo de novo methylation during pancreatic carcinogenesis. Methylation of some CpG islands is cancer-specific  
25 while others show tissue-specific patterns of methylation.

### **BRIEF DESCRIPTION OF THE FIGURES**

**Figure 1** shows the representative results of MCIPs isolated by MCA/RDA. Dot blot analysis. 1A, An example of kinetic enrichment of methylated sequences by

RDA. MCA products from the driver and the tester (PL8) and the PCR products from first (1st SA), second (2nd SA) and third (3rd SA) competitive hybridization/selective amplification were blotted onto the membrane and hybridized with a labeled Cyclin G probe. 1B, Dot blot analysis using MICPs isolated from MCA/RDA as probes. First  
 5 three MICPs were hybridized only to the tester (either PL3 or PL8), whereas the next three MICPs were weakly hybridized to the driver as well as the tester.

**Figure 2** shows a CpG plot across the 5' CpG islands of Cyclin G and ppENK showing the relation between isolated clones and their corresponding genes. The positions of MSP primers are also indicated. The black boxes represent exons.

**Figure 3** shows a summary of the average level of methylation of selected  
 10 MCA/RDA MICPs by bisulfite-modified genomic sequencing. The specimen number and the age of the patients are in the left column. *Empty oval*, 0-10% methylation; *white oval with black dots*, 11-30% methylation; *black oval with white dots*, 31-70% methylation; *black oval*, 71-100% methylation; -, not determined. *NP*, normal  
 15 pancreas; *PCa*, primary pancreatic adenocarcinoma.

**Figure 4** shows MSP analyses of MICP36 (A) and MICP25 (B) in primary pancreatic adenocarcinomas and normal tissues. The PCR products in the lanes U and M indicate the presence of unmethylated and methylated templates, respectively. *PCa*, primary pancreatic carcinoma, *NP*, normal pancreas, *NC*, normal colonic  
 20 mucosa. Expression of Cyclin G (C) and ppENK (D) in pancreatic cancer cell lines and normal pancreata by RT-PCR analysis. Cyclin G and ppENK were coamplified with GAPDH to ensure the RNA integrity. Cyclin G was expressed at low level in the methylated cell line PL8 compared with unmethylated cell lines (PL3, CAPAN2, MiaPaca2, and Panc1) and four normal pancreata. 5 Aza-dC treatment increased  
 25 Cyclin G expression in PL8. All methylated cell lines examined (PL3, CAPAN2, MiaPaca2 and Panc1) lacked expression of ppENK, whereas all three normal pancreata expressed ppENK. Treatment of four cell lines with 5 Aza-dC restored the ppENK expression. The expected sizes of the PCR products are 306 bp for GAPDH, 207 bp for Cyclin G, and 179 bp for ppENK.

**Figure 5** shows aberrant methylation of MICPs and clinicopathological variables. Multivariate linear regression analysis was used to determine the relationship between the number of aberrantly methylated MICPs in a pancreatic adenocarcinoma and the variables patient age (left plot) and tumor diameter (right plot). For each decade increase in age, the average number of methylated loci increases by 0.28, regardless of the tumor diameter. For each increase in tumor diameter (in cm), the number of methylated loci increases by 0.156 regardless of patient age.

**Figure 6a-6i** shows the nucleic acid sequence for SEQ ID NO:1-42.

10

### **DETAILED DESCRIPTION OF THE INVENTION**

It has been determined that an aberrant methylation state of nucleic acids in certain genes, particularly regulatory sequences, is diagnostic for the presence or potential development of a cellular proliferative disorder in subjects bearing the aberrantly methylated nucleic acids. More particularly, the hypermethylation of certain nucleotides localized in CpG islands has been shown to affect the expression of genes associated with the CpG islands; typically such hypermethylated genes have reduced or abolished expression, primarily due to down-regulated transcription. Using a recently developed PCR-based technique called methylated CpG island amplification (MCA), several nucleic acid molecules aberrantly methylated in pancreatic cancer cells line were identified.

Of the 42 unique clones isolated using MCA/RDA, seven (Cyclin G, ppENK, MICP20, 23, 33, 35 and 36) were CpG islands aberrantly methylated in pancreatic carcinoma compared to normal pancreas. Indeed, none of these 7 clones, were methylated in a panel of normal pancreata using the highly sensitive method of MSP. Two of these seven clones corresponded to the 5' CpG island of the genes ppENK and Cyclin G. ppENK encodes opioid growth factor, also known as [Met5]-enkephalin. This opioid peptide induces apoptosis in lung cancer cell lines (Maneckjee & Minna, Cell Growth Differ. 5:1033-1040, 1994) and several studies have demonstrated that

this peptide has a negative growth regulatory effect on various kinds of cancers, including pancreatic cancer (Zagon, et al., *Int. J. Oncol.* 14:577-584, 1999). Aberrant methylation of the 5' CpG island of ppENK was found in 87% of primary pancreatic carcinomas. Hypermethylation was associated with transcriptional silencing of this gene in pancreatic cancer cell lines. Although a low level of methylation in other normal mucosae by MSP was also observed, these results indicate that de novo methylation of 5' CpG islands and transcriptional repression of ppENK might contribute to pancreatic carcinogenesis.

Cyclin G is a target for transcriptional activation by p53 (Okamoto, et al., *Embo. J.* 13:48616-4822, 1994). Conflicting functions for Cyclin G have been reported. When overexpressed Cyclin G is associated with cell growth in vitro (Smith, et al., *Exp. Cell. Res.* 230:61-68, 1997), while increased expression of Cyclin G also augments apoptosis of multiple cancer cell lines in response to different stimuli (Okamoto & Prives, *Oncogene* 18:4606-4615, 1999). The data demonstrate the association between hypermethylation of the 5' CpG island of Cyclin G and its transcriptional repression in the pancreatic cancer cell line PL8 (Fig. 4C), suggesting that Cyclin G could have been selected for silencing because of tumor suppressive functions. These data extend previous findings demonstrating aberrant methylation of multiple cancer-related genes including p16 and hMLH1 in pancreatic cancer (Ueki, et al., *Cancer Res.* 60:1835-1839, 2000).

Methylation of several clones in pancreata with chronic pancreatitis was also observed. Two of the 5 pancreata with chronic pancreatitis harbored aberrant methylation and one of these two pancreata contained a PanIN lesion and this latter sample displayed methylation of 3 clones. Previous studies demonstrated that chronic pancreatitis is a significant risk factor of development of pancreatic cancer (Lowenfels, et al., *N. Engl. J. Med.* 328:1433-1437, 1993) and duct lesions (PanIN) often found in chronic pancreatitis are considered as the precursors of infiltrating pancreatic carcinoma (Hruban, et al., *Clin. Cancer Res.* 6:2969-2972, 2000). The presence of aberrant methylation in DNA from chronic pancreatitis suggests that de novo methylation of CpG islands may be an early event in pancreatic cancer

development in this setting. Additional studies are needed to determine the role and the timing of de novo methylation of CpG islands in progression model of pancreatic cancer (Hruban, et al., Clin. Cancer Res. 6:2969-2972, 2000). The absence of methylated templates of MICP33 and 35 in any normal tissue examined raises the possibility that MSP could be used to detect aberrant methylation of these clones in clinical samples such as stool, blood, or pancreatic fluid, for the early detection of pancreatic cancers.

Three additional known genes containing methylated 5' CpG islands in pancreatic cancers were identified (GAD1, ECEL1 and PAX5). These genes were isolated by MCA/RDA because relatively fewer DNA templates were methylated in normal pancreas. Some genes that are methylated in cancer and in only a small percentage of normal cells may appear to undergo selection during carcinogenesis (Salem, et al., Cancer Res. 60:2473-2476, 2000), but are merely unselected epigenetic markers of stem cells that have evolved to cancers by other clonal selection events. This phenomenon is important to be aware of when studying methylation in human cancer and makes it much more difficult to assign causality to methylation phenomena in cancers compared to genetic events such as homozygous deletion. For normally unmethylated genes whose function is well characterized such as hMLH1, or for genes that are methylated as a second hit for a tumor suppressor gene (e.g. VHL, E-cadherin), or for tumor suppressor genes alternatively targeted by genetic and epigenetic inactivation (e.g. p16 and RB) (Baylin, et al., Adv. Cancer Res. 72:141-196, 1998), the biological significance of "aberrant methylation" is well accepted. As additional genes are identified that are methylated in pancreatic cancer, it will be important to rule out low-level methylation using sensitive techniques such as MSP (Herman, et al., Proc. Natl. Acad. Sci. USA 93:9821-9826, 1996) before such genes are accepted as having undergone selection through methylation.

Three CpG islands that were differentially methylated in pancreatic cancer but were not located within 5' regions of their corresponding genes were also identified, CSX, MCT3 and ICAM5. The role of hypermethylation of non-5' CpG islands need to be defined, but recent studies have shown that aberrant methylation in cancer is not

confined to the 5' region but can occur in internal exons and 3' regions of genes (Costello, et al., Nat. Genet. 24:132-138, 2000, Liang, et al., Genomics 53:260-268, 1998). It is probable that several of the unknown clones identified are genes whose expression is repressed by aberrant methylation. For example, GRAIL and

5 GENSCAN programs suggest putative coding exons downstream of MICP23 and MICP33.

In addition to identifying CpG islands with cancer-related methylation, CpG islands that were methylated in both normal pancreata and neoplastic tissues were isolated. Methylation of non-neoplastic colorectal (Ahuja, et al., Cancer Res. 58:5489-5494, 1998, Toyota, et al., Proc. Natl. Acad. Sci. USA 96:8681-8686, 1999),

10 bladder and prostate tissues (Liang, et al., Genomics 53:260-268, 1998) has been observed for several genes and CpG islands. Methylation in normal tissues that is not the result of imprinting is frequently "age-related." This has been best shown in the colonic mucosa for genes such as ER (Ahuja, et al., Cancer Res. 58:5489-5494, 1998,

15 Toyota, et al., Proc. Natl. Acad. Sci. USA 96:8681-8686, 1999). However, normal pancreata used in this study were obtained from 14 patients (mean age of 62) and for at least 5 of these clones there was no evidence of age-related methylation (Fig. 3). This suggests that the aberrant methylation observed in the pancreatic cancers in this study is not simply a function of age. Some of the clones listed in Table 1 could

20 undergo age-related methylation, but to demonstrate this would require many more normal pancreata. Methylation of ppENK, MICP20 and 23 in a significant percentage of the DNA templates within normal gastric, duodenal and colonic mucosae highlights the tissue specific nature of DNA methylation. This low level methylation of different normal tissues might also explain some of the tumor-specific methylation patterns

25 observed by others (Costello, et al., Nat. Genet. 24:132-138, 2000). The data indicate that there are tissue-specific methylation patterns in normal tissues (Liang, et al., Genomics 53:260-268, 1998) and age-related methylation changes are probably restricted to certain genes and/or tissues (Ahuja, et al., Cancer Res. 58:5489-5494, 1998).

In this study, the MCA/RDA technique was modified and these modifications may have improved the efficiency of the MCA/RDA technique. Betaine was included in the PCR reaction and amplified the methylated templates under a higher annealing temperature (77°C). The combination of betaine and DMSO can uniformly amplify a mixture of DNA with different GC content (Baskaran, et al., *Genome Res.* 6:633-638, 1996). These modifications might have enhanced the amplification of distinct clones instead of Alu repetitive sequences that accounted for 60% of the recovered clones using the original protocol (Toyota, et al., *Cancer Res.* 59:2307-2312, 1997). The subtractive and kinetic enrichment of differentially methylated sequence by RDA as shown in this study (Fig. 1A) may have advantages over other techniques to isolate differentially methylated sequences between normal tissue and cancer (Costello, et al., *Nat. Genet.* 24:132-138, 2000, Liang, et al., *Genomics* 53:260-268, 1998). MCA/RDA, however, has limitations for identifying differentially methylated sequences. First, MCA only detects differentially methylated sequences with two restriction enzyme sites (SmaI in this study). Second, MCA/RDA not only identifies absolute differences in methylation between the tester and the driver, it also will identify methylated sequences both in the tester and the driver if for example, there is low level methylation in the driver (normal pancreas). Third, some clones that appeared to be unmethylated by dot-blot hybridization were indeed methylated by bisulfite sequencing in normal pancreata (MICP15, Fig. 1B and Fig. 4C). Finally, even if bisulfite sequencing suggests that there is no methylation of a clone in normal pancreata, it is important to rule out low-level methylation in normal tissues using a sensitive technique, such as MSP.

The results indicate that aberrant methylation of CpG islands is a common event in pancreatic carcinogenesis. Some de novo methylated CpG islands could serve as cancer-specific markers while others reflect tissue specific pattern of DNA methylation.

Methylated nucleic acid sequences are also provided. For the first time, the present invention provides methylated chemical structures for MICP 1-42 (see Table 1). One of skill in the art can now readily locate the CpG-rich sequences associated

with these genes and identify such methylated forms of the genes/regulatory sequences by methods described herein (The gene sequences can be identified in a gene database found at <http://www.ncbi.nlm.nih.gov/UniGene/index.html>). The invention provides CpG-rich regions from the above genes as set forth in SEQ ID Nos 1-42, equivalent to MICP 1-42, respectively.

The term "polynucleotide" or "nucleic acid sequence" refers to a polymeric form of nucleotides at least 10 bases in length. An "isolated polynucleotide" is a polynucleotide that is not immediately contiguous with both of the coding sequences with which it is immediately contiguous (one on the 5' end and one on the 3' end) in the naturally occurring genome of the organism from which it is derived. Thus, an isolated polynucleotide may include a coding region with its associated regulatory sequences. The term therefore includes, for example, a recombinant DNA which is incorporated into a vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (e.g., a cDNA) independent of other sequences. The nucleotides of the invention can be ribonucleotides, deoxyribonucleotides, or modified forms of either nucleotide. Specifically, methylated forms of nucleotides in a polynucleotide sequence are also included. The term includes single and double forms of DNA.

As will be understood by those of skill in the art, when the sequence is RNA, the deoxynucleotides A, G, C, and T of SEQ ID NO:1-42, are replaced by ribonucleotides A, G, C, and U, respectively. Also included in the invention are fragments of the above-described nucleic acid sequences that are at least 15 bases in length, which is sufficient to permit the fragment to selectively hybridize to DNA that encodes polypeptides encoded by SEQ ID NO:1-42. The term "selectively hybridize" refers to hybridization under moderately or highly stringent conditions (See, Sambrook, as cited herein) which excludes non-related nucleotide sequences.

The nucleic acid sequence includes the disclosed sequence and sequences that encode conservative variations of the polypeptides encoded by polynucleotides provided herein. The term "conservative variation" as used herein denotes the



replacement of an amino acid residue by another, biologically similar residue. Examples of conservative variations include the substitution of one hydrophobic residue such as isoleucine, valine, leucine or methionine for another, or the substitution of one polar residue for another, such as the substitution of arginine for lysine, glutamic for aspartic acid, or glutamine for asparagine, and the like. The term  
5 “conservative variation” also includes the use of a substituted amino acid in place of an unsubstituted parent amino acid provided that antibodies raised to the substituted polypeptide also immunoreact with the unsubstituted polypeptide.

Nucleic acid sequences of the invention can be expressed in vitro by DNA  
10 transfer into a suitable host cell. “Host cells” are cells in which a vector can be propagated and its DNA expressed. The cell may be prokaryotic or eukaryotic. The term also includes any progeny of the subject host cell. It is understood that all progeny may not be identical to the parental cell since there may be mutations that occur during replication. However, such progeny are included when the term “host  
15 cells” is used. Methods of stable transfer, meaning that the foreign DNA is continuously maintained in the host, are known in the art.

In one aspect, the nucleic acid sequences may be inserted into an expression vector. The term “expression vector” refers to a plasmid, virus or other vehicle known in the art that has been manipulated by insertion or incorporation of the  
20 sequence of interest genetic sequences. Polynucleotide sequence which encode sequence of interest can be operatively linked to expression control sequences. “Operatively linked” refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. An expression control sequence operatively linked to a coding sequence is ligated such  
25 that expression of the coding sequence is achieved under conditions compatible with the regulatory or expression control sequences. As used herein, the terms “regulatory sequences” and “expression control sequences” refers to nucleic acid sequences that regulate the expression of a nucleic acid sequence to which it is operatively linked. Expression control sequences are operatively linked to a nucleic acid sequence when  
30 the expression control sequences control and regulate the transcription and, as

appropriate, translation of the nucleic acid sequence. Thus expression control sequences can include appropriate promoters, enhancers, transcription terminators, a start codon (i.e., ATG) in front of a protein-encoding gene, splicing signal for introns, maintenance of the correct reading frame of that gene to permit proper translation of mRNA, and stop codons. The terms "regulatory sequences" and "expression control sequences" are intended to include, at a minimum, components whose presence can influence expression, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences. An example of an expression control sequence includes a promoter.

A "promoter" is a minimal sequence sufficient to direct transcription. Also included in the invention are those promoter elements which are sufficient to render promoter-dependent gene expression controllable for cell-type specific, tissue-specific, or inducible by external signals or agents; such elements may be located in the 5' or 3' regions of the gene. Both constitutive and inducible promoters, are included in the invention (see, e.g., Bitter et al., *Methods in Enzymology* 153:516-544, 1987). For example, when cloning in bacterial systems, inducible promoters such as pL of bacteriophage plac, ptrp, ptac (ptrp-lac hybrid promoter) and the like may be used. When cloning in mammalian cell systems, promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the retrovirus long terminal repeat; the adenovirus late promoter; the vaccinia virus 7.5K promoter) may be used. Promoters produced by recombinant DNA or synthetic techniques may also be used to provide for transcription of the nucleic acid sequences of the invention.

In the present invention, the polynucleotide sequences may be inserted into an expression vector which contains a promoter sequence which facilitates the efficient transcription of the inserted genetic sequence of the host. The expression vector typically contains an origin of replication, a promoter, as well as specific genes which allow phenotypic selection of the transformed cells. Vectors suitable for use in the present invention include, but are not limited to the T7-based expression vector for expression in bacteria (Rosenberg et al., *Gene* 56:125, 1987), the pMSXND

expression vector for expression in mammalian cells (Lee and Nathans, J. Biol. Chem. 263:3521, 1988) and baculovirus-derived vectors for expression in insect cells. The DNA segment can be present in the vector operably linked to regulatory elements, for example, a promoter (e.g., T7, metallothionein I, or polyhedron promoters).

5 Polynucleotide sequences of the invention can be expressed in either prokaryotes or eukaryotes. Hosts can include microbial, yeast, insect and mammalian organisms. Methods of expressing DNA sequences having eukaryotic or viral sequences in prokaryotes are well known in the art. Biologically functional viral and plasmid DNA vectors capable of expression and replication in a host are known in the  
10 art. Such vectors are used to incorporate DNA sequences of the invention.

“Transformation” means a genetic change induced in a cell following incorporation of new DNA (i.e., DNA exogenous to the cell). Where the cell is a mammalian cell, the genetic change is generally achieved by introduction of the DNA into the genome of the cell (i.e., stable).

15 Thus, a “transformed cell” is a cell into which (or into an ancestor of which) has been introduced, by means of recombinant DNA techniques, a DNA molecule encoding sequence of interest. Transformation of a host cell with recombinant DNA may be carried out by conventional techniques as are well known to those skilled in the art. Where the host is prokaryotic, such as E. coli, competent cells which are  
20 capable of DNA uptake can be prepared from cells harvested after exponential growth phase and subsequently treated by the CaCl<sub>2</sub> method using procedures well known in the art. Alternatively, MgCl<sub>2</sub> or RbCl can be used. Transformation can also be performed after forming a protoplast of the host cell if desired.

When the host is a eukaryote, such methods of transfection of DNA as calcium  
25 phosphate co-precipitates, conventional mechanical procedures such as microinjection, electroporation, insertion of a plasmid encased in liposomes, or virus vectors may be used. Eukaryotic cells can also be cotransformed with DNA sequences encoding the sequence of interest, and a second foreign DNA molecule

encoding a selectable phenotype, such as the herpes simplex thymidine kinase gene. Another method is to use a eukaryotic viral vector, such as simian virus 40 (SV40) or bovine papilloma virus, to transiently infect or transform eukaryotic cells and express the protein (see for example, Eukaryotic Viral Vectors, Cold Spring Harbor Laboratory, Gluzman ed., 1982).

Isolation and purification of microbial expressed polypeptide, or fragments thereof, provided by the invention, may be carried out by conventional means including preparative chromatography and immunological separations involving monoclonal or polyclonal antibodies.

In one embodiment, the invention provides substantially purified polypeptide encoded by polynucleotide sequences SEQ ID NO:1-42. The term "substantially purified" as used herein refers to a polypeptide which is substantially free of other proteins, lipids, carbohydrates or other materials with which it is naturally associated. One skilled in the art can purify a polypeptide sequence using standard techniques for protein purification. The substantially pure polypeptide will yield a single major band on a non-reducing polyacrylamide gel. The purity of the polypeptide can also be determined by amino-terminal amino acid sequence analysis.

Minor modifications of the primary amino acid sequences may result in proteins which have substantially equivalent activity as compared to the unmodified counterpart polypeptide described herein. Such modifications may be deliberate, as by site-directed mutagenesis, or may be spontaneous. All of the polypeptides produced by these modifications are included herein as long as the biological activity still exists.

The polypeptides of the invention also include dominant negative forms of the invention polypeptide which do not have the biological activity of invention polypeptide sequence. A "dominant negative form" of invention is a polypeptide that is structurally similar to invention polypeptide but does not have wild-type invention function. For example, a dominant-negative invention polypeptide may interfere with

wild-type invention function by binding to, or otherwise sequestering, regulating agents, such as upstream or downstream components, that normally interact functionally with the invention polypeptide.

To identify genes differentially methylated in colorectal cancer, methylated  
5 CpG island amplification was used followed by representational difference analysis (Razin and Cedar, Cell 17: 473-476, 1994, herein incorporated by reference). One of the clones recovered (MINT31, see U.S. Patent Application Serial No. 09/309,175, incorporated by reference herein in its entirety) mapped to human chromosome 17q21 using a radiation hybrid panel. A Blast search revealed this fragment to be completely  
10 identical to part of a BAC clone (Genbank: AC004590) sequenced by high throughput genomic sequencing. The region surrounding MINT31 fulfills the criteria of a CpG island: GC content 0.67, CpG/GpC ratio 0.78 and a total of 305 CpG sites in a 4 kb region. Using this CpG island and 10 kb of flanking sequences in a Blast analysis, several regions highly homologous to the rat T-type calcium channel gene,  
15 CACNA1G, were identified (Perez-Reyes et al., Nature 391: 896-900, 1998, herein incorporated by reference). Several ESTs were also identified in this region. Using Genscan, 2 putative coding sequences (G1, and G2) were identified. Blastp analysis revealed that G1 has a high homology to the EH-domain-binding protein, epsin, while G2 is homologous to a *C. elegans* hypothetical protein (accession No. 2496828).

20 Due to the clear correlation between methylation of CpG islands and cellular proliferative disorders, in another embodiment of the present invention, there are provided methods for detecting a cellular proliferative disorder in a subject having or at risk for said cellular proliferative disorder. The method includes assaying, in nucleic acid-containing specimen taken from said subject, the methylation state of a  
25 gene or its associated regulatory regions, wherein the expression state of the gene or its associated regulatory regions is associated with the presence of the cellular proliferative disorder, and identifying as having a cellular proliferative disorder a subject that has aberrant methylation of regions of said gene. The method provides for detecting a cellular proliferative disorder in a subject having or at risk for said cellular  
30 proliferative disorder by identifying aberrantly methylation of regions of a gene when

compared to the same regions of the gene in a subject not having said cellular proliferative disorder.

The aberrant methylation comprises hypermethylated CpG rich regions (i.e., islands). In one aspect of the present invention, the CpG rich regions are associated with the invention genes gene, and affect the expression thereof in a methylation state-dependent manner.

A “cell proliferative disorder” or “cellular proliferative disorder” is any disorder in which the proliferative capabilities of the affected cells is different from the normal proliferative capabilities of unaffected cells. An example of a cell proliferative disorder is neoplasia. Malignant cells (i.e., cancer) develop as a result of a multistep process. Specific, non-limiting examples of cell proliferative disorders associated with increased methylation of CpG-islands are low grade astrocytoma, anaplastic astrocytoma, glioblastoma, medulloblastoma, gastric cancer, colorectal cancer, colorectal adenoma, acute myelogenous leukemia, lung cancer, renal cancer, pancreatic cancer, leukemia, breast cancer, prostate cancer, endometrial cancer and neuroblastoma.

A cell proliferative disorder as described herein may be a neoplasm. Such neoplasms are either benign or malignant. The term “neoplasm” refers to a new, abnormal growth of cells or a growth of abnormal cells that reproduce faster than normal. A neoplasm creates an unstructured mass (a tumor) which can be either benign or malignant. For example, the neoplasm may be a head, neck, lung, esophageal, stomach, small bowel, colon, bladder, kidney, or cervical neoplasm. The term “benign” refers to a tumor that is noncancerous, e.g. its cells do not proliferate or invade surrounding tissues. The term “malignant” refers to a tumor that is metastastic or no longer under normal cellular growth control.

A cell proliferative disorder may be an age-associated disorder. Examples of age-associated disorders which are cell proliferative disorders include colon cancer, lung cancer, breast cancer, prostate cancer, and melanoma, amongst others.

A "nucleic acid containing specimen" includes any type of material containing a nucleic acid to be subject to invention methods. The nucleic acid may be contained in a biological sample. Such samples include but are not limited to any bodily fluid, such as a serum, urine, saliva, blood, cerebrospinal fluid, pleural fluid, ascites fluid, sputum, stool, or a biopsy sample.

Samples or specimens include any CpG-rich DNA sequence, whatever the origin, as long as the sequence is detectably present in a sample. While routine diagnostic tests may not be able to identify cancer cells in these samples, the method of the present invention identifies neoplastic cells derived from the primary tumor or from a metastases. The method includes non-invasive sampling (e.g., bodily fluid) as well as invasive sampling (e.g., biopsy). The sample of DNA of the subject may be serum, plasma, lymphocytes, urine, sputum, bile, stool, cervical tissue, saliva, tears, pancreatic juice, duodenal juice, cerebral spinal fluid, regional lymph node, histopathologic margins, and any bodily fluid that drains a body cavity or organ. Therefore, the method provides for the non-invasive detection of various tumor types including head and neck cancer, lung cancer, esophageal cancer, stomach cancer, small bowel cancer, colon cancer, bladder cancer, kidney cancers, cervical cancer and any other organ type that has a draining fluid accessible to analysis. For example, neoplasia of regional lymph nodes associated with a primary mammary tumor can be detected using the method of the invention. Regional lymph nodes for head and neck carcinomas include cervical lymph nodes, prelaryngeal lymph nodes, pulmonary juxta-esophageal lymph nodes and submandibular lymph nodes. Regional lymph nodes for mammary tissue carcinomas include the axillary and intercostal nodes. Samples also include urine DNA for bladder cancer or plasma or saliva DNA for head and neck cancer patients.

Any nucleic acid sample, in purified or nonpurified form, can be utilized as the starting nucleic acid or acids in accordance with the present invention, provided it contains, or is suspected of containing, a nucleic acid sequence containing a target locus (e.g., CpG-containing nucleic acid). In general, the CpG-containing nucleic acid is DNA. However, invention methods may employ, for example, samples that contain

DNA, or DNA and RNA, including messenger RNA, wherein DNA or RNA may be single stranded or double stranded, or a DNA-RNA hybrid may be included in the sample. A mixture of nucleic acids may also be employed. The specific nucleic acid sequence to be detected may be a fraction of a larger molecule or can be present  
5 initially as a discrete molecule, so that the specific sequence constitutes the entire nucleic acid. It is not necessary that the sequence to be studied be present initially in a pure form; the nucleic acid may be a minor fraction of a complex mixture, such as contained in whole human DNA. The nucleic acid-containing sample used for detection of methylated CpG may be from any source including, but not limited to,  
10 brain, colon, urogenital, lung, renal, pancreas, liver, esophagus, stomach, hematopoietic, breast, thymus, testis, ovarian, and uterine tissue, and may be extracted by a variety of techniques such as that described by Maniatis, et al. (Molecular Cloning: a Laboratory Manual, Cold Spring Harbor, NY, pp 280, 281, 1982).

The nucleic acid of interest can be any nucleic acid where it is desirable to  
15 detect the presence of a differentially methylated CpG island. The CpG island comprises a CpG island located in a gene or regulatory region for a gene. A "CpG island" is a CpG rich region of a nucleic acid sequence. The nucleic acid sequence may include, for example, MICP 1-42. However, any gene or nucleic acid sequence of interest containing a CpG sequence can provide diagnostic information (i.e., via its  
20 methylation state) using invention methods.

Moreover, these markers can also be multiplexed in a single amplification reaction to generate a low cost, reliable cancer screening test for many cancers simultaneously.

A combination of DNA markers for CpG-rich regions of nucleic acid may be  
25 amplified in a single amplification reaction. The markers are multiplexed in a single amplification reaction, for example, by combining primers for more than one locus. For example, DNA from a urine sample can be amplified with three different randomly labeled primer sets, such as those used for the amplification of the MICP38-42 loci, in the same amplification reaction. The reaction products are separated on a



denaturing polyacrylamide gel, for example, and then exposed to film for visualization and analysis. By analyzing a panel of markers, there is a greater probability of producing a more useful methylation profile for a subject.

If the sample is impure (e.g., plasma, serum, stool, ejaculate, sputum, saliva, cerebrospinal fluid, or blood or a sample embedded in paraffin), it may be treated before amplification with a reagent effective for lysing the cells contained in the fluids, tissues, or animal cell membranes of the sample, and for exposing the nucleic acid(s) contained therein. Methods for purifying or partially purifying nucleic acid from a sample are well known in the art (e.g., Sambrook et al., Molecular Cloning: a Laboratory Manual, Cold Spring Harbor Press, 1989, herein incorporated by reference).

In order to detect a differential methylation state for a gene or CpG-containing region of interest, invention methods include any means known in the art for detecting such differential methylation. For example, detecting the differential methylation may include contacting the nucleic acid-containing specimen with an agent that modifies unmethylated cytosine, amplifying a CpG-containing nucleic acid in the specimen by means of CpG-specific oligonucleotide primers, wherein the oligonucleotide primers distinguish between modified methylated and nonmethylated nucleic acid, and detecting the methylated nucleic acid based on the presence or absence of amplification products produced in said amplifying step. This embodiment includes the PCR-based methods described in U.S. Patent No. 5,786,146, incorporated herein in its entirety.

For the first time, the methylation state of a number of genes has been correlated with cell proliferative disorders. Examples of such genes and their NCBI accession numbers, including the location of the clone, are set out in Table 1.

In another embodiment, detection of differential methylation is accomplished by contacting a nucleic acid sample suspected of comprising a CpG-containing nucleic acid with a methylation sensitive restriction endonuclease that cleaves only

unmethylated CpG sites under conditions and for a time to allow cleavage of un-  
methylated nucleic acid. The sample is further contacted with an isoschizomer of  
the methylation sensitive restriction endonuclease, that cleaves both methylated and  
unmethylated CpG-sites, under conditions and for a time to allow cleavage of  
5 methylated nucleic acid. Oligonucleotides are added to the nucleic acid sample under  
conditions and for a time to allow ligation of the oligonucleotides to nucleic acid  
cleaved by the restriction endonuclease, and the digested nucleic acid is amplified by  
conventional methods such as PCR wherein primers complementary to the  
oligonucleotides are employed. Following identification, the methylated CpG-  
10 containing nucleic acid can be cloned, using method well known to one of skill in the  
art (see Sambrook et al., Molecular Cloning: a Laboratory Manual, Cold Spring  
Harbor Press, 1989).

As used herein, a "methylation sensitive restriction endonuclease" is a  
restriction endonuclease that includes CG as part of its recognition site and has altered  
15 activity when the C is methylated as compared to when the C is not methylated.  
Preferably, the methylation sensitive restriction endonuclease has inhibited activity  
when the C is methylated (e.g., SmaI). Specific non-limiting examples of a  
methylation sensitive restriction endonucleases include Sma I, BssHII, or HpaII. Such  
enzymes can be used alone or in combination. Other methylation sensitive restriction  
20 endonucleases will be known to those of skill in the art and include, but are not  
limited to SacII, EagI, and BstUI, for example. An "isoschizomer" of a methylation  
sensitive restriction endonuclease is a restriction endonuclease which recognizes the  
same recognition site as a methylation sensitive restriction endonuclease but which  
cleaves both methylated and unmethylated CGs. One of skill in the art can readily  
25 determine appropriate conditions for a restriction endonuclease to cleave a nucleic  
acid (see Sambrook et al., Molecular Cloning: a Laboratory Manual, Cold Spring  
Harbor Press, 1989). Without being bound by theory, actively transcribed genes  
generally contain fewer methylated CGs than in other genes.

In one embodiment of the invention, a nucleic acid of interest is cleaved with a  
30 methylation sensitive endonuclease. In one aspect, cleavage with the methylation

sensitive endonuclease creates a sufficient overhang on the nucleic acid of interest. Following cleavage with the isoschizomer, the cleavage product can still have a sufficient overhang. An "overhang" refers to nucleic acid having two strands wherein the strands end in such a manner that a few bases of one strand are not base paired to the other strand. A "sufficient overhang" refers to an overhang of sufficient length to allow specific hybridization of an oligonucleotide of interest. In one embodiment, a sufficient overhang is at least two bases in length. In another embodiment, the sufficient overhang is four or more bases in length. An overhang of a specific sequence on the nucleic acid of interest may be desired in order for an oligonucleotide of interest to hybridize. In this case, the isoschizomer can be used to create the overhang having the desired sequence on the nucleic acid of interest.

In another aspect of this embodiment, the cleavage with a methylation sensitive endonuclease results in a reaction product of the nucleic acid of interest that has a blunt end or an insufficient overhang. In this embodiment, an isoschizomer of the methylation sensitive restriction endonuclease can create a sufficient overhang on the nucleic acid of interest. "Blunt ends" refers to a flush ending of two stands, the sense stand and the antisense strand, of a nucleic acid.

Once a sufficient overhang is created on the nucleic acid of interest, an oligonucleotide is ligated to the nucleic acid cleaved of interest which has been cleaved by the methylation specific restriction endonuclease. "Ligation" is the attachment of two nucleic acid sequences by base pairing of substantially complementary sequences and/or by the formation of covalent bonds between two nucleic acid sequences. In one aspect of the present invention, an "oligonucleotide" is a nucleic acid sequence of about 2 up to about 40 bases in length. It is presently preferred that the oligonucleotide is from about 15 to 35 bases in length.

In one embodiment, an adaptor is utilized to create DNA ends of desired sequence and overhang. An "adaptor" is a double-stranded nucleic acid sequence with one end that has a sufficient single-stranded overhang at one or both ends such that the adaptor can be ligated by base-pairing to a sufficient overhang on a nucleic

acid of interest that has been cleaved by a methylation sensitive restriction enzyme or an isoschizomer of a methylation sensitive restriction enzyme. Adaptors can be obtained commercially, or two oligonucleotides can be utilized to form an adaptor. Thus, in one embodiment, two oligonucleotides are used to form an adaptor; these  
5 oligonucleotides are substantially complementary over their entire sequence except for the region(s) at the 5' and/or 3' ends that will form a single stranded overhang. The single stranded overhang is complementary to an overhang on the nucleic acid cleaved by a methylation sensitive restriction enzyme or an isoschizomer of a methylation sensitive restriction enzyme, such that the overhang on the nucleic acid of interest will  
10 base pair with the 3' or 5' single stranded end of the adaptor under appropriate conditions. The conditions will vary depending on the sequence composition (GC vs AT), the length, and the type of nucleic acid (see Sambrook et al., Molecular Cloning: a Laboratory Manual, 2nd Ed.; Cold Spring Harbor Laboratory Press, Plainview, NY, 1998).

15 Following the ligation of the oligonucleotide, the nucleic acid of interest is amplified using a primer complementary to the oligonucleotide. Specifically, the term "primer" as used herein refers to a sequence comprising two or more deoxyribo-nucleotides or ribonucleotides, preferably more than three, and more preferably more than eight, wherein the sequence is capable of initiating synthesis of a primer  
20 extension product, which is substantially complementary to a nucleic acid such as an adaptor or a ligated oligonucleotide. Environmental conditions conducive to synthesis include the presence of nucleoside triphosphates and an agent for polymerization, such as DNA polymerase, and a suitable temperature and pH. The primer is preferably single stranded for maximum efficiency in amplification, but may be double stranded.  
25 If double stranded, the primer is first treated to separate its strands before being used to prepare extension products. In one embodiment, the primer is an oligodeoxyribo-nucleotide. The primer must be sufficiently long to prime the synthesis of extension products in the presence of the inducing agent for polymerization. The exact length of primer will depend on many factors, including temperature, buffer, and nucleotide

composition. The oligonucleotide primer typically contains 12-20 or more nucleotides, although it may contain fewer nucleotides.

Primers of the invention are designed to be "substantially" complementary to each strand of the oligonucleotide to be amplified and include the appropriate G or C nucleotides as discussed above. This means that the primers must be sufficiently complementary to hybridize with their respective strands under conditions which allow the agent for polymerization to perform. In other words, the primers should have sufficient complementarity with a 5' and 3' oligonucleotide to hybridize therewith and permit amplification of CpG containing nucleic acid sequence.

Primers of the invention are employed in the amplification process which is an enzymatic chain reaction that produces exponential quantities of target locus relative to the number of reaction steps involved (e.g., polymerase chain reaction or PCR). Typically, one primer is complementary to the negative (-) strand of the locus and the other is complementary to the positive (+) strand. Annealing the primers to denatured nucleic acid followed by extension with an enzyme, such as the large fragment of DNA Polymerase I (Klenow) and nucleotides, results in newly synthesized + and - strands containing the target locus sequence. Because these newly synthesized sequences are also templates, repeated cycles of denaturing, primer annealing, and extension results in exponential production of the region (i.e., the target locus sequence) defined by the primer. The product of the chain reaction is a discrete nucleic acid duplex with termini corresponding to the ends of the specific primers employed.

The oligonucleotide primers of the invention may be prepared using any suitable method, such as conventional phosphotriester and phosphodiester methods or automated embodiments thereof. In one such automated embodiment, diethylphosphoramidites are used as starting materials and may be synthesized as described by Beaucage, et al. (Tetrahedron Letters, 22:1859-1862, 1981). One method for synthesizing oligonucleotides on a modified solid support is described in U.S. Patent No. 4,458,066.

Where the CpG-containing nucleic acid sequence of interest contains two strands, it is necessary to separate the strands of the nucleic acid before it can be used as a template for the amplification process. Strand separation can be effected either as a separate step or simultaneously with the synthesis of the primer extension products.

5 This strand separation can be accomplished using various suitable denaturing conditions, including physical, chemical, or enzymatic means, the word "denaturing" includes all such means. One physical method of separating nucleic acid strands involves heating the nucleic acid until it is denatured. Typical heat denaturation may involve temperatures ranging from about 80° to 105°C for times ranging from about 1

10 to 10 minutes. Strand separation may also be induced by an enzyme from the class of enzymes known as helicases or by the enzyme RecA, which has helicase activity, and in the presence of riboATP, is known to denature DNA. The reaction conditions suitable for strand separation of nucleic acids with helicases are described by Kuhn Hoffmann-Berling (CSH-Quantitative Biology, 43:63, 1978) and techniques for using

15 RecA are reviewed in C. Radding (Ann. Rev. Genetics, 16:405-437, 1982).

When complementary strands of nucleic acid or acids are separated, regardless of whether the nucleic acid was originally double or single stranded, the separated strands are ready to be used as a template for the synthesis of additional nucleic acid strands. This synthesis is performed under conditions allowing hybridization of

20 primers to templates to occur. Generally synthesis occurs in a buffered aqueous solution, generally at a pH of about 7-9. Preferably, a molar excess (for genomic nucleic acid, usually about 108:1 primer:template) of the two oligonucleotide primers is added to the buffer containing the separated template strands. It is understood, however, that the amount of complementary strand may not be known if the process

25 of the invention is used for diagnostic applications, so that the amount of primer relative to the amount of complementary strand cannot be determined with certainty. As a practical matter, however, the amount of primer added will generally be in molar excess over the amount of complementary strand (template) when the sequence to be amplified is contained in a mixture of complicated long-chain nucleic acid strands. a

30 large molar excess is preferred to improve the efficiency of the process.

The deoxyribonucleoside triphosphates dATP, dCTP, dGTP, and dTTP are added to the synthesis mixture, either separately or together with the primers, in adequate amounts and the resulting solution is heated to about 90°-100°C from about 1 to 10 minutes, preferably from 1 to 4 minutes. After this heating period, the solution is allowed to cool to approximately room temperature, which is preferable for the primer hybridization. To the cooled mixture is added an appropriate agent for effecting the primer extension reaction (called herein "agent for polymerization"), and the reaction is allowed to occur under conditions known in the art. The agent for polymerization may also be added together with the other reagents if it is heat stable. This synthesis (or amplification) reaction may occur at room temperature up to a temperature above which the agent for polymerization no longer functions. Thus, for example, if DNA polymerase is used as the agent, the temperature is generally no greater than about 40°C. Most conveniently the reaction occurs at room temperature.

The agent for polymerization may be any compound or system which will function to accomplish the synthesis of primer extension products, including enzymes. Suitable enzymes for this purpose include, for example, E. coli DNA polymerase I, Klenow fragment of E. coli DNA polymerase I, T4 DNA polymerase, other available DNA polymerases, polymerase muteins, reverse transcriptase, and other enzymes, including heat-stable enzymes (i.e., those enzymes which perform primer extension after being subjected to temperatures sufficiently elevated to cause denaturation such as Taq DNA polymerase, and the like). Suitable enzymes will facilitate combination of the nucleotides in the proper manner to form the primer extension products which are complementary to each locus nucleic acid strand. Generally, the synthesis will be initiated at the 3' end of each primer and proceed in the 5' direction along the template strand, until synthesis terminates, producing molecules of different lengths. There may be agents for polymerization, however, which initiate synthesis at the 5' end and proceed in the other direction, using the same process as described above.

Preferably, the method of amplifying is by PCR, as described herein and as is commonly used by those of ordinary skill in the art. However, alternative methods of amplification have been described and can also be employed. PCR techniques and

many variations of PCR are known. Basic PCR techniques are described by Saiki et al. (1988 Science 239:487-491) and by U.S. Pat. Nos. 4,683,195, 4,683,202 and 4,800,159, which are incorporated herein by reference.

The conditions generally required for PCR include temperature, salt, cation, pH and related conditions needed for efficient copying of the master-cut fragment. PCR conditions include repeated cycles of heat denaturation (i.e. heating to at least about 95.degree. C.) and incubation at a temperature permitting primer: adaptor hybridization and copying of the master-cut DNA fragment by the amplification enzyme. Heat stable amplification enzymes like the pwo, *Thermus aquaticus* or *Thermococcus litoralis* DNA polymerases are commercially available which eliminate the need to add enzyme after each denaturation cycle. The salt, cation, pH and related factors needed for enzymatic amplification activity are available from commercial manufacturers of amplification enzymes.

As provided herein an amplification enzyme is any enzyme which can be used for in vitro nucleic acid amplification, e.g. by the above-described procedures. Such amplification enzymes include pwo, *Escherichia coli* DNA polymerase I, Klenow fragment of *E. coli* DNA polymerase I, T4 DNA polymerase, T7 DNA polymerase, *Thermus aquaticus* (Taq) DNA polymerase, *Thermococcus litoralis* DNA polymerase, SP6 RNA polymerase, T7 RNA polymerase, T3 RNA polymerase, T4 polynucleotide kinase, Avian Myeloblastosis Virus reverse transcriptase, Moloney Murine Leukemia Virus reverse transcriptase, T4 DNA ligase, *E. coli* DNA ligase or Q.beta. replicase. Preferred amplification enzymes are the pwo and Taq polymerases. The pwo enzyme is especially preferred because of its fidelity in replicating DNA.

Once amplified, the nucleic acid can be attached to a solid support, such as a membrane, and can be hybridized with any probe of interest, to detect any nucleic acid sequence. Several membranes are known to one of skill in the art for the adhesion of nucleic acid sequences. Specific non-limiting examples of these membranes include nitrocellulose (NITROPURE) or other membranes used in for detection of gene



expression such as polyvinylchloride, diazotized paper and other commercially available membranes such as GENESCREEN, ZETAPROBE (Biorad), and NYTRAN Methods for attaching nucleic acids to these membranes are well known to one of skill in the art. Alternatively, screening can be done in a liquid phase.

5           In nucleic acid hybridization reactions, the conditions used to achieve a particular level of stringency will vary, depending on the nature of the nucleic acids being hybridized. For example, the length, degree of complementarity, nucleotide sequence composition (e.g., GC v. AT content), and nucleic acid type (e.g., RNA v. DNA) of the hybridizing regions of the nucleic acids can be considered in selecting  
10   hybridization conditions. An additional consideration is whether one of the nucleic acids is immobilized, for example, on a filter.

          An example of progressively higher stringency conditions is as follows: 2 x SSC/0.1% SDS at about room temperature (hybridization conditions); 0.2 x SSC/0.1% SDS at about room temperature (low stringency conditions); 0.2 x  
15   SSC/0.1% SDS at about 42°C (moderate stringency conditions); and 0.1 x SSC at about 68°C (high stringency conditions). Washing can be carried out using only one of these conditions, e.g., high stringency conditions, or each of the conditions can be used, e.g., for 10-15 minutes each, in the order listed above, repeating any or all of the steps listed. However, as mentioned above, optimal conditions will vary, depending  
20   on the particular hybridization reaction involved, and can be determined empirically. In general, conditions of high stringency are used for the hybridization of the probe of interest.

          The probe of interest can be detectably labeled, for example, with a radioisotope, a fluorescent compound, a bioluminescent compound, a  
25   chemiluminescent compound, a metal chelator, or an enzyme. Those of ordinary skill in the art will know of other suitable labels for binding to the probe, or will be able to ascertain such, using routine experimentation.

In one embodiment, representational difference analysis (RDA, see Lisitsyn et al., Science 259:946-951, 1993, herein incorporated by reference) can be performed on CpG-containing nucleic acid following MCA. MCA utilizes kinetic and subtractive enrichment to purify restriction endonuclease fragments present in one population of nucleic acid fragments but not in another. Thus, RDA enables the identification of small differences between the sequences of two nucleic acid populations. RDA uses nucleic acid from one population as a "tester" and nucleic acid from a second population as a "driver" in order to clone probes for single copy sequences present in (or absent from) one of the two populations. In one embodiment, nucleic acid from a "normal" individual or sample, not having a disorder such as a cell-proliferative disorder is used as a "driver," and nucleic acid from an "affected" individual or sample, having the disorder such as a cell proliferative disorder is used as a "tester." In one embodiment, the nucleic acid used as a "tester" is isolated from an individual having a cell proliferative disorder such as low grade astrocytoma, anaplastic astrocytoma, glioblastoma, medulloblastoma, gastric cancer, colorectal cancer, colorectal adenoma, acute myelogenous leukemia, leukemia, lung cancer, renal cancer, breast cancer, prostate cancer, endometrial cancer and neuroblastoma. The nucleic acid used as a "driver" is thus normal astrocytes, normal glial cells, normal brain cells, normal gastric cells, normal colorectal cells, normal leukocytes, normal lung cells, normal kidney cells, normal breast cells, normal prostate cells, normal uterine cells, and normal neurons, respectively. In an additional embodiment, the nucleic acid used as a "driver" is isolated from an individual having a cell proliferative disorder such as low grade astrocytoma, anaplastic astrocytoma, glioblastoma, medulloblastoma, gastric cancer, colorectal cancer, colorectal adenoma, acute myelogenous leukemia, leukemia, lung cancer, renal cancer, breast cancer, prostate cancer, endometrial cancer and neuroblastoma. The nucleic acid used as a "tester" is thus normal astrocytes, normal glial cells, normal brain cells, normal gastric cells, normal colorectal cells, normal leukocytes, normal lung cells, normal kidney cells, normal breast cells, normal prostate cells, normal uterine cells, and normal neurons, respectively. One of skill in the art will readily be able to identify the

“tester” nucleic acid useful with to identify methylated nucleic acid sequences in given “driver” population.

The materials for use in the assay of the invention are ideally suited for the preparation of a kit. Therefore, in accordance with another embodiment of the present invention, there is provided a kit it useful for the detection of a cellular proliferative disorder in a subject having or at risk for said cellular proliferative disorder. Invention kits include a carrier means compartmentalized to receive a sample in close confinement therein, one or more containers comprising a first container containing a reagent which modifies unmethylated cytosine and a second container containing primers for amplification of a CpG-containing nucleic acid, wherein the primers distinguish between modified methylated and nonmethylated nucleic acid, and optionally, a third container containing a methylation sensitive restriction endonuclease. Primers contemplated for use in accordance with the invention include those that would amplify sequences or fragments thereof as set forth in SEQ ID NOs: 1-42.

Carrier means are suited for containing one or more container means such as vials, tubes, and the like, each of the container means comprising one of the separate elements to be used in the method. In view of the description provided herein of invention methods, those of skill in the art can readily determine the apportionment of the necessary reagents among the container means. For example, one of the container means can comprise a container containing an oligonucleotide for ligation to nucleic acid cleaved by a methylation sensitive restriction endonuclease. One or more container means can also be included comprising a primer complementary to the oligonucleotide. In addition, one or more container means can also be included which comprise a methylation sensitive restriction endonuclease. One or more container means can also be included containing an isoschizomer of said methylation sensitive restriction enzyme.

It should be noted that as used herein and in the appended claims, the singular forms “a,” “and,” and “the” include plural referents unless the context clearly dictates

otherwise. Thus, for example, reference to "a cell" includes a plurality of such cells and reference to "the restriction enzyme" includes reference to one or more restriction enzymes and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs. Although any methods, devices and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, the preferred methods, devices and materials are now described.

All publications mentioned herein are incorporated herein by reference in full for the purpose of describing and disclosing the methodologies which are described in the publications which might be used in connection with the presently described invention. The publications discussed above and throughout the text are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior invention.

The following example is intended to illustrate but not to limit the invention in any manner, shape, or form, either explicitly or implicitly. While they are typical of those that might be used, other procedures, methodologies, or techniques known to those skilled in the art may alternatively be used.

20

### **EXAMPLE 1**

#### **Collection and Preparation of Pancreatic Cell Lines**

The following pancreatic adenocarcinoma cell lines were used: PL3 and PL8 (both CIMP-cell lines (CpG island methylator phenotype) were from Dr. Elizabeth Jaffe, John Hopkins University); CAPAN1, CAPAN2, Panc1, Hs766T, and MiaPaca2 (from the American Type Culture Collection, Rockville, MD) and Colo357 (from the European Collection of Animal Cell Cultures, Salisbury, United Kingdom). In addition, seventeen pancreatic cancer xenografts were selected at random from a total

25

of 90 xenografts, which were established from the primary carcinomas as described in Ueki, et al., Cancer Res., 60:1835-1839, 2000. Forty-seven primary pancreatic adenocarcinomas, 15 normal pancreata, 5 pancreata from patients with chronic pancreatitis, and a panel of normal tissues were obtained from the resected surgical specimens at The Johns Hopkins Medical Institutions, Baltimore, MD. Frozen tissues or paraffin-embedded tissues were microdissected to obtain >40% neoplastic cellularity in the primary pancreatic adenocarcinomas, and 3 of the 15 frozen normal pancreatic tissues were also microdissected to enrich the normal ductal epithelium. DNA was extracted from microdissected primary pancreatic adenocarcinomas and normal tissues as well as from lymphocytes of four cancer-free individuals using standard methods.

## **EXAMPLE 2**

### **Methylated CpG Island Amplification / Representational Difference Analysis (MCA/RDA)**

MCA/RDA was performed as described by Toyota et al., Cancer Res., 59:2307-2312, 1999, modifying such procedure to increase the efficiency by digesting 5µg of DNA with *Sma*I and *Xma*I (New England Biolabs). The restriction fragments were then ligated to RMCA adapter and amplified by PCR in 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl<sub>2</sub>, 50 mM KCl, 0.5 M betaine, 2% DMSO, 200 µM each deoxynucleotide triphosphate, 100 pmol of RMCA 24mer primer and 15 units of Taq polymerase (Life Technologies, Inc.) in a final reaction volume of 100 µl. The reaction mixture was then incubated at 72°C for 5 min and at 95°C for 3 min, and then subjected to 25 cycles of 1 min at 95°C and 3 min at 77°C followed by a final extension of 10 min at 77°C. Betaine was included in the PCR reaction to help amplify the methylated templates at a higher annealing temperature (77°C). The combination of betaine and DMSO can uniformly amplify a mixture of DNA with different GC content (Baskaran, et al., Genome Res. 6:633-638, 1996). These modifications might have enhanced the amplification of distinct MICPs (methylated in carcinoma of the pancreas) instead of Alu repetitive sequences that accounted for 60% of the recovered clones using the original protocol (Toyota et al., Cancer Res.

59:2307-2312, 1999). The MCA amplicon from either the pancreatic cancer cell line PL3 or PL8 was used as the tester for RDA, and a MCA amplicon generated from a mixture of DNA from the normal pancreata of six different patients was used as the driver. RDA was performed on these MCA amplicons using different adapters, JMCA and NMCA. Sequences of adapters used for MCA/RDA are listed in Table 3A and 3B and are available at <http://pathology2.jhu.edu/pancreas/prim0425.htm>, which website is incorporated herein by reference. After the third round of competitive hybridization and selective amplification, the RDA difference products of second and third round amplifications were cloned into pBluescript II plasmid vector (Stratagene).

### EXAMPLE 3

#### DNA Sequencing of Clones and Dot Blot Hybridization

The clones recovered from each cell line after MCA/RDA were amplified with T3 and T7 primers and then sequenced using KS primer as recommended by the manufacturer (Sequitern Excel; Epicentre Technologies). To determine the methylation status of MCA/RDA MICPs in pancreatic cancer and normal pancreas, MICPs were screened by hybridizing them to a dot blot of MCA products of pancreatic cancers and normal pancreata. Plasmid DNA containing each independent clone was prepared and digested with *Sma*I. DNA fragments were recovered from agarose gel and used as a probe for dot blot hybridization. Aliquots (1 µl) of the mixture of 10XSSC and MCA products from the driver and from the tester (PL3 and PL8) both before and after each of the three rounds of RDA competitive hybridization/selective amplification were blotted onto nylon membranes in duplicate. Similarly, MCA products from six pancreatic cell lines (CAPAN1, CAPAN2, Panc1, Hs766T, MiaPaca2, and Colo357) and from eight other normal pancreata were also blotted onto the membranes. The membranes were hybridized with <sup>32</sup>P-labeled probes overnight, washed, and exposed to a Kodak X-ray film.

**EXAMPLE 4****Bisulfite Modification, Bisulfite-Modified Genomic Sequencing, and Methylation-Specific PCR (MSP)**

The bisulfite treatment was carried out for 16 h at 50°C using 1 µg of genomic DNA, as described in Ueki, et al., Cancer Res., 60:1835-1839, 2000. Genomic sequencing was performed on bisulfite-treated DNA to examine the methylation status of 10–20 CpG dinucleotides located in and/or around *Sma*I sites of each clone in 22 pancreatic tissues (8 cancer cell lines, 6 primary adenocarcinomas, and 8 normal pancreata; Ueki, et al., Cancer Res. 60:1835-1839, 2000). Genomic sequencing of the coding sequence of *cyclin G* was also performed in PL8. The level of methylation of each clone was determined by quantifying the level of methylation of each CpG site by comparing the intensity of unconverted cytosine with that of cytosine plus thymidine. Generally, in pancreatic cancer cell lines, the level of methylation observed at each CpG dinucleotide was consistent throughout the CpG island. Therefore, the average level of methylation of each sequence was graded and placed into one of 4 grades: 0–10%, 11–30%, 31–70%, and 71–100%. MSP was performed as described in Herman, et al., Proc. Natl. Acad. Sci. USA 93:9821-9826, 1996, and to acquire optimal specificity, each primer pair contained four to six CpG sites, and high specific annealing temperatures were used. The primers and the specific annealing temperatures for each clone are listed in Table 3 and are available at <http://pathology2.jhu.edu/pancreas/prim0425.htm>, which website is incorporated herein by reference. If validated MSP primers sets specific for methylated and unmethylated templates revealed that there was only amplification of methylated templates, the samples are presumed to be 100% methylated. Methylated and unmethylated templates were identified by bisulfite-modified sequencing. In describing MSP results performed on CpG islands that were normally unmethylated in non-neoplastic pancreas, a cancer sample was termed “methylated” if MSP yielded any methylated templates.

### EXAMPLE 5

#### Reverse Transcription-PCR (RT-PCR) and 5-aza-2'-deoxycytidine (5Aza-dC) Treatment

Five pancreatic cancer cell lines (PL3, PL8, CAPAN2, Panc1, and MiaPaca2) and four normal pancreata were used for RT-PCR analysis. The cell lines were treated with demethylating agent 5Aza-dC (Sigma Chemical Co.) at a final concentration of 1  $\mu$ M for 5 days. Total RNA was prepared using TRIzol (Life Technologies, Inc.), reverse-transcribed and amplified. As a control for cDNA integrity, glyceraldehyde-3-phosphate dehydrogenase gene (*GAPDH*) was also amplified. Primer sequences for RT-PCR are listed in Table 3 and are available at <http://pathology2.jhu.edu/pancreas/prim0425.htm>, which website is incorporated herein by reference.

### EXAMPLE 6

#### Statistics

The primary outcome variable was the observed number of 7 MICP loci found to be methylated in 64 pancreatic cancers. Wilcoxon's rank-sum test compared the observed number of methylated loci by tumor differentiation (poorly *versus* well or moderately differentiated), lymph node status (0 or 1 *versus* >1 node positive), and prior CIMP classification (CIMP positive *versus* CIMP negative). Simple linear regression assessed the relationship between the observed number of methylated loci and these covariates: age, age squared, and tumor diameter (in cm). Multivariate linear regression assessed the simultaneous contribution of the clinicopathological and demographic variables to the observed number of methylated loci. All of the tests were two-sided. A *P* of < 0.05 signified statistical significance.



## **EXAMPLE 7**

### **Patient Population and Tissue Samples**

Normal and tumor specimens were obtained from pancreatic adenocarcinomas resected at The Johns Hopkins Hospital. Pancreatic cancer xenografts were established from the primary carcinomas as previously described in Caldas, et al., Nature Genet. 8:27-31, 1994, and carcinoma and normal tissues were stored at -70°C. Thirty-two xenografts were selected at random. Three MSI carcinoma xenografts were added, as reported previously, as well as another MSI primary carcinoma (Goggins, et al., Am. J. of Pathology 152:1501-1507, 1998). Genomic DNA was prepared from 35 xenografts and 9 pancreatic adenocarcinoma cell lines (BxPc3, Capan1, Capan2, Panc1, CFPAC1, MiaPaca2, Hs766T (all from ATCC, Rockville, MD), Co10357 (from ECACC, Salisbury, UK) and PL45, a low passage cell line established in the Goggin Laboratory at John Hopkins University School of Medicine). Where available, DNA was obtained from primary pancreatic cancer tissue frozen at -80C since Whipple resection. Frozen tissues were microdissected to obtain DNA from normal pancreatic tissue and the pancreatic carcinoma.

Patient records were reviewed to determine a history of cigarette smoking, diabetes mellitus, and prognosis, and a family history of pancreatic cancer. These data were reviewed in the context of the DNA methylation data.

## **EXAMPLE 8**

### **Bisulfite Modification and Genomic Sequencing**

The bisulfite treatment was carried out for 16h at 56°C on 1µg of genomic DNA, according to the procedure of Herman et al, Proc. Natl. Acad. Sci. USA 93:9821-9826, 1996. Modified DNA was purified and eluted into 50µl of LoTE buffer. The primers used for genomic sequencing of bisulfite-treated DNA are listed in Table 3 and are available at <http://pathology2.jhu.edu/pancreas/prim0425.htm>, which website is incorporated herein by reference. PCR was performed on 1-2µl of

bisulfite-treated DNA, and prior to sequencing, PCR reactions were incubated with exonuclease I and shrimp alkaline phosphatase (Amersham, according to the manufacturer recommendations). Sequencing of PCR products was performed in microtiter plates as recommended by the manufacturer (Sequitheer Excel, Epicentre Technologies, Madison, WI).

### **EXAMPLE 9**

#### **Methylation-Specific PCR (MSP) Assay**

The methylation status of each gene was determined by MSP as described by Herman et al, Proc. Natl. Acad. Sci. USA 93:9821-9826, 1996, in which the sequence difference of bisulfite-treated DNA was detected by PCR using primers specific for either the methylated or for the unmethylated DNA. Primer sequences and the specific annealing temperatures for 13 genes are listed in Table 3 and are available at <http://pathology2.jhu.edu/pancreas/prim0425.htm>, which website is incorporated herein by reference. MSP was performed on 1 µl of bisulfite-treated DNA under the conditions as follows: 95°C for 3 min; then 35-40 cycles of 95°C for 30s, the specific annealing temperature for 30s, and 72°C for 30s; and a final extension of 4 min at 72°C. Five µl of each PCR product were directly loaded onto 3% agarose gels or 10% acrylamide gels, stained with ethidium bromide and visualized under UV illumination. All PCR reactions were performed with positive controls for both unmethylated and methylated alleles, and no DNA control. Finally, 3-6 CpG sites were included in each primer pair and the specific annealing temperatures were used for each gene to obtain optimal specificity.

### **EXAMPLE 10**

#### **Identification of differentially methylated sequences**

The strategy of MCA/RDA has been previously reported (Toyota, et al., Cancer Res. 59:2307-2312, 1997). Ninety-six randomly selected clones recovered from each cell line were subjected to DNA sequencing and 66 clones were revealed to

be independent. Only 3 clones contained Alu-repetitive sequences. The subsequent probing of labeled clones to MCA products of tester and driver by dot-blot hybridization revealed that 43 of 66 clones (MICP1-43) were differentially methylated in the tester compared to the driver (Fig, 1). These 43 clones were also variably methylated in the other 6 pancreatic cancer cell lines examined. A description of these 43 differentially methylated clones is shown in Table 1. All of the 43 clones had a GC content of greater than 50% and 41 (95%) had a sequence uniqueness sustaining the criteria of CpG island (Gardiner-Garden & Frommer, J. Mol. biol. 196:261-282, 1987). The DNA homology search of each clone with the BLAST program (National Center for Biotechnology Information) demonstrated that 84% (36) of the 43 clones had significant homologies to known human sequences, including 8 clones matched to human gene sequences and 9 clones matched to human ESTs. Five clones were also matched or contained a part of CpG islands isolated previously (Toyota, et al., Cancer Res. 59:2307-2312, 1997, Cross, et al., Nat. Genet., 6:236-244, 1994) and 14 clones had significant homology to High-Throughput Genome Sequences in the three International Nucleotide Sequence databases: DDBJ, EMBL and GenBank. The remaining 7 had no significant homology to known sequences. MICP1 corresponded to the 3' noncoding region of the human homeobox gene CSX, MICP2 corresponded to exon 1 and intron 1 of the human Cyclin G, MICP3 corresponded to 5' region of the human endothelin-converting enzyme-like 1 gene ECEL1, MICP4 corresponded to intron 1 of the human glutamate decarboxylase 1 gene GAD1, MICP5 corresponded to exon 7 to exon 9 of the human ICAM5, MICP6 corresponded to intron 2 to intron 3 of the human monocarboxylate transporter 3 gene MCT3, MICP7 corresponded to the 5' region of the human B-cell specific transcriptional factor gene PAX5, MICP8 corresponded to intron 1 and exon 2 of the human Preproenkephalin gene (ppENK) (Fig. 2). Interestingly, 3 clones (MICP1, 17 and 22) matched to CpG islands originally recovered from colorectal cancer cell line using the same technique (named MINT 23, 20 and 32, respectively) (Toyota, et al., Cancer Res. 59:2307-2312, 1997).

**EXAMPLE 11****Characterization of the sequences**

For 30 of the 43 clones, methylation was detected in 2 or more out of 8 normal pancreata by dot blot analysis, suggesting that these clones could be frequently  
5 methylated in normal pancreas. Therefore, only the remaining 13 clones were further analyzed by bisulfite sequencing. For seven of the clones (Cyclin G, ppENK, MICP20, 23, 33, 35 and 36), methylation was restricted to pancreatic cancers (Fig. 4A and 4B). In the case of 5 clones (MCT3, PAX5, MICP15, 16 and 38), methylation was detectable in DNA from normal pancreata as well as DNA from cancer tissues  
10 (Fig. 3C). In the thirteenth clone (MICP42), cytosines at CpG sites were similarly methylated in both pancreatic cancers and normal pancreata. The sequence uniqueness of this clone also did not satisfy the criteria for CpG islands. A summary of the level of methylation of each clone is shown in Fig. 3D. There was little individual variation in the level of methylation of these 6 clones (MCT3, PAX5,  
15 MICP15, 16, 38 and 42) in normal pancreata from 8 patients at the age from 34 to 84 years old (Fig. 3 and data not shown). Interestingly, the methylation of these CpG islands in normal pancreata was sometimes heterogeneous. For example, although the SmaI site of MICP15 was not methylated in normal pancreata, 2 CpG sites near the SmaI site were methylated (Fig. 3C). A summary of the results of MCA/RDA and  
20 bisulfite sequencing is also provided in Fig. 4.

In order to identify low level of methylation of identified clones in pancreatic tissues, MSP primers were designed for the 7 clones (Cyclin G, ppENK, MICP20, 23, 33, 35 and 36) differentially methylated in pancreatic cancers by bisulfite sequencing. The methylation status of these clones was examined in 15 primary pancreatic  
25 adenocarcinomas, 5 DNA samples from pancreata with chronic pancreatitis as well as 14 normal pancreata including three specimens enriched in normal ductal epithelium. For MICP36, MSP detected methylation in DNA of three pancreatic cancer cell lines but not in any other specimens examined. Aberrant methylation of the remaining 6 clones was detected in 7% to 87% of primary pancreatic adenocarcinomas, while MSP

confirmed a lack of methylation of these 6 clones in DNA from 14 normal pancreata (Fig. 5 and Table 2A and 2B). DNA from one chronic pancreatitis tissue containing pancreatic intraductal neoplasia (PanIN) (Hruban, et al., Clin. Cancer Res. 6:2969-2972, 2000) harbored methylated templates of Cyclin G, ppENK and MICP20 and  
5 DNA from another chronic pancreatitis sample also had methylated templates of ppENK.

Because tissue-specific methylation differences can be found in normal tissues (Liang, et al., Genomics 53:260-268, 1998), the clones found that were aberrantly methylated in pancreatic cancer, as compared to normal pancreas, were also analyzed  
10 to see if they are methylated in other normal tissues. By MSP, MICPs 33 and 35 were not methylated in any normal gastrointestinal tissues, while ppENK, MICP20 and 23 were methylated in DNA samples from normal gastric, duodenal and colonic mucosae (Fig. 5 and Table 2A and 2B). Amplification of methylated templates of these clones was always weak in normal mucosae compared to the primary pancreatic  
15 adenocarcinomas (Fig. 3), suggesting that there were few methylated DNA templates in these mucosae.

### **EXAMPLE 12**

#### **Expression of Cyclin G and ppENK in pancreatic cancer**

To determine whether methylation of these clones resulted in loss or decrease  
20 of gene expression, Cyclin G and ppENK were further examined using RT-PCR in 5 and 4 pancreatic cell lines, respectively. Partial methylation (~50%) of the 5' CpG island of Cyclin G in PL8 (Fig. 4C) was associated with decreased expression of Cyclin G by RT-PCR. The 5' CpG island of Cyclin G was not methylated in a panel of normal pancreata. Cyclin G was expressed in 4 normal pancreata by RT-PCR.  
25 Treatment with 5Aza-dC restored the expression of Cyclin G in PL8 (Fig 4C). Using RT-PCR, it was found that ppENK was expressed in normal pancreata but not in any of the 4 pancreatic cancer cell lines examined in which 5'CpG island of this gene was methylated. 5Aza-dC treatment restored ppENK expression in all 4 cell lines (Fig.

4D). Thus, hypermethylation of the 5' CpG islands of Cyclin G and ppENK is coincides with decreased expression in pancreatic cancers.

### **EXAMPLE 13**

#### **Determination of Methylated ppENK by Methylation Specific PCR of Pancreatic 5                      Fluid as a Specific Marker of Pancreatic Cancer**

Pancreatic fluid obtained from patients undergoing pancreatic surgical resection from 38 patients with pancreatic cancer, 7 with chronic pancreatitis, 4 with miscellaneous tumors (islet cell, serous cyst adenoma, and lymphoma), 9 with ampullary cancers, 9 with IPMNs (intraductal papillary mucinous neoplasms) and 3  
10 from bile duct cancers was analyzed. Methylated ppENK was detected in 55% of pancreatic cancer fluids, none in the chronic pancreatitis or other miscellaneous tumor group, 2 of 9 with IPMN, 2 of 3 with bile duct cancer, and 4 of 9 with ampullary cancer, suggesting that the specificity of methylated ppENK in pancreatic fluid is useful as a diagnostic marker.

15                      Although the invention has been described with reference to the presently preferred embodiment, it should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims.

**TABLE 1 A**

The 42 MICPs identified by MCA/RDA in pancreatic cancers\*

MICP	Blast homology	Size (bp)	CpG Islands**	Chromosome
1	<i>CSX</i>	414	yes	5q35
2	<i>Cyclin G</i>	392	yes	5q32-34
3	<i>FLJ00083</i>	479	no	not known
4	<i>GADJ</i>	309	yes	2
5	<i>HLH</i>	179	yes	20
6	<i>ICAM5</i>	630	yes	19p13.2
7	<i>MCT3</i>	308	yes	22q12.3-q31.2
8	<i>PAX5</i>	548	yes	9p13
9	<i>ppENK</i>	255	yes	8q23-q24
10	<i>SMO</i>	229	yes	7q34-q36
11	<i>ZBP</i>	399	yes	5q22
12	Human EST	431	yes	Xp22
13	Human EST	600	yes	3p
14	Human EST	510	yes	5
15	Human EST	359	yes	not known
16	Human EST	370	yes	12q
17	Human EST	324	yes	6q
18	Human EST	415	yes	11q
19	Human EST	392	yes	not known
20	Human EST	359	yes	11q14
21	Human EST	545	yes	19q13.3
22	Human CpG island	386	yes	7q34-q36
23	Human CpG island	464	yes	20q13
24	Human CpG island	526	yes	15
25	Human CpG island	280	yes	6p22.1-23
26	Human CpG island	422	yes	1
27	Human genomic DNA	257	yes	17
28	Human genomic DNA	350	yes	7q34-q36
29	Human genomic DNA	336	yes	10
30	Human genomic DNA	293	yes	2q36-q37
31	Human genomic DNA	427	yes	13
32	Human genomic DNA	470	no	21q22.3
33	Human genomic DNA	264	yes	Xq22.1-23
34	Human genomic DNA	371	yes	20p11.21-11.23
35	Human genomic DNA	445	yes	4
36	Human genomic DNA	357	yes	19q13.1
37	Human genomic DNA	312	yes	7p14-15
38	Human genomic DNA	372	yes	5
39	No homology	307	yes	not known
40	No homology	331	yes	not known
41	No homology	304	yes	not known
42	No homology	307	yes	not known

\* 7 of these 42 MICPs were methylated in pancreatic cancer and not normal pancreas (see text)

\*\* minimal length, 200bp; GC content, &gt;50%; CpG/GpC, &gt;0.5(11)

**TABLE 1B**

MICP*	Size	%GC	CpG/GpC	CpG Islands?	NCBI Acc. #**	Location of clone***
1	414	64.3	0.811	yes	AF135523	1-414
2	392	62.8	0.613	yes	D86077	35-426
3	479	63.9	0.444	no	AK024484	1645-2107
4	309	64.4	0.727	yes	AC007405	72554-72862
5	179	68.3	1.330	yes	AL121673	66270-66448
6	630	65.6	0.625	yes	AF082802	5502-6131
7	308	66.6	0.704	yes	AF132611	1082-1389
8	548	60.4	0.683	yes	AL161781	129660-130226
9	255	67.8	0.867	yes	V00509	622-876
10	229	58.2	0.927	yes	AC083866	37615-37843
11	399	59.1	0.800	yes	AC016663	106325-106723
12	431	68.4	0.909	yes	AC002365	159360-159790
13	600	65.5	0.661	yes	AC024167	62307-62906
14	510	63.7	0.771	yes	AF135520	1-510
15	359	65.5	0.972	yes	AW028607	259-376
16	370	64.9	1.030	yes	AC026336	11182-11568
17	324	67.6	0.816	yes	AC068247	66045-66347
18	415	61.9	0.767	yes	AP002781	190243-190537
19	392	55.1	1.214	yes	AI557774	193-392
20	359	55.6	0.731	yes	AP002354	58648-59006
21	545	65.0	1.023	yes	AC007785	13354-13898
22	386	66.3	0.605	yes	AC005998	48200-48585
23	464	65.7	0.975	yes	AF135532	1-464
24	526	64.2	0.645	yes	AC074201	59279-59804
25	280	68.1	0.929	yes	AL136305	115130-115409
26	422	63.0	0.767	yes	AL137797.1	38754-39186
27	257	65.8	0.852	yes	AC004706	88868-89124
28	350	64.9	0.900	yes	AC004897	60876-61125
29	336	64.4	0.606	yes	AC005661	43755-44090
30	293	67.0	0.760	yes	AC012033	113181-113473
31	427	66.7	0.884	yes	AC013721	31973-32339
32	470	59.6	0.292	no	AJ239326	83971-84440
33	264	63.3	0.580	yes	AL035088	102596-102859
34	371	63.0	0.722	yes	AL080312	56645-57015
35	445	64.0	0.884	yes	AC023868	130032-030491
36	357	68.9	0.800	yes	AC002133	31977-32333
37	312	67.5	0.885	yes	AC005826	151694-152005
38	372	65.6	0.778	yes	AC011376	56983-57313
39	307	68.7	0.844	yes	no homology	
40	331	70.7	0.707	yes	no homology	
41	304	68.8	0.794	yes	no homology	
42	307	68.7	0.875	yes	no homology	

\* Total 4 clones with no homology to known human sequences (MICP38-42) and 38 clones matched to  
 11 clones matched to the human genes (MICP1-11)  
 10 clones matched to human ESTs (MICP12-21)



TABLE 2A

Sample	age	Tumor Diam.(cm)	nodes	no. methylated	CpG Island						zbp
					ppENK	MICP27	MICP38	MICP25	MICP36	CyclinG	
A9PC1				3							
B1PC3				3							
CAPAN1				3							
CAPAN2				3							
CFPAC				2							
Colo357				5							
Hs766T				3							
MiaPaca2				4							
Panc1				2							
PL3				5							
PL8				4							
Px17	69	4.4	+	2							
Px29	66	2.5	+	3							
Px30	57	3.0	+	0							
Px64	76	2.5	+	1							
Px65	63	2.2	+	1							
Px74	83	3.5	+	2							
Px75	63	5.0	0	2							
Px76	64	2.2	+	3							
Px102	47	3.0	0	1							
Px108	76	3.0	+	2							
Px120	70	5.0	+	4							
Px132	61	3.6	+	3							
Px143	54	2.0	+	1							
Px184	59	4.0	+	4							
Px186	55	4.0	+	2							
Px195	67	4.0	+	0							
Px282	79	3.0	0	2							
1	64	4.7	0	1							
2	67	3.0	+	2							
4	54	2.7	+	2							
6	69	4.5	+	2							
9	85	8.0	+	4							
11	65	2.5	+	0							
12	81	10.0	+	2							
13	53		+	1							
14	57	3.0	+	2							
196	84	5.0	+	4							
198	76	4.0	+	3							
240	50	3.5	0	0							
248	67	2.0	+	1							
281	36	6.0	+	1							
287	72	2.5	0	1							
666	34	8.0	+	4							
5350	44	4.0	+	0							
11632	66	6.5	+	2							
12616	58	8x		1							
13671	58	8.0	+	1							
13653	63	14.5	+	3							
17498	73	3.5	+	3							
20852	78	5.0	+	2							
21190	82	3.5	+	3							
21889	80	4.0	+	3							
22384	74	2.0	+	3							
24494	78	3.5	+	1							
24721	71	2.5	+	2							
25392	57	3.0	+	1							
26183	56	1.5	0	2							
30011	65	4.0	+	3							
30845	76	2.6	+	3							
31742	66	1.5	0	1							
32008	61		0	2							
36083	69	1.5	+	1							
35583	75	3.0	+	1							
36378	74	5.2	+	2							
37880	43	4.0	0	1							
42946	71	3.5	+	2							
45885	53	8x		3							
46391	79	2.3	+	2							
49126	49	4.0	+	1							
49390	78	2.5	+	3							
52150	72	7.0	0	3							
52225	58	3.5	+	3							
53413	85	3.5	+	2							
55090	71	4.5	+	1							

**TABLE 2B**

## Results of MSP

	n°	CLONE 2 Cyclin G	CLONE 8 PPEVK	CLONE 20	CLONE 23	CLONE 33	CLONE 35	CLONE 36
Primary pancreatic carcinoma	15	7%	87%	13%	53%	33%	40%	0%
Normal pancreata	14	0%	0%	0%	0%	0%	0%	0%
Chronic pancreatitis	5	20%	40%	20%	0%	0%	0%	ND
Normal gastric mucosae	6	ND	ND	50%	17%	0%	0%	ND
Normal duodenal mucosae	8	ND	100%**	50%	75%	0%	0%	ND
Normal colonic mucosae	6	ND	100%***	33%	100%	0%	0%	ND
Normal lymphocytes	4	0%	0%	0%	0%	0%	0%	ND

\* number examined

\*\* only 4 samples examined

\*\*\* only 3 samples examined

**TABLE 3A****PRIMER SEQUENCE FOR BISULFITE-SEQUENCE**

Clone	Orientation	Sequence	Annealing Temperature	SEQ ID NO:
RARβ	Forward	5'-GAGTTGGTGATGTTAGATTAG-3'	56	43
	Reverse	5'-TTCCCAAAAAAATCCCAAATTC-3'		44
	Sequence	5'-CTCCTTCCAAATAAATACTTAC-3'		45
THBS1	Forward	5'-AGAGAGGAGTTTAGATTGG-3'	54	46
	Reverse	5'-CAAAAAAACTAAAACCTCAAC-3'		47
	Sequence	Forward primer		
CACNA1G	Forward	5'-TGGATAAAGGATGTTTGGGGTTTG-3'	55, 53, 51, 49*	48
	Reverse	5'-CCCTCCCCTTACCCCTAAATCC-3'		49
	Sequence	5'-ACTCCCCCTCACTTTATTC-3'		50
hMLH1	Forward	5'-ATTATTTTAGTAGAGGTATATAAG-3'	58	51
	Reverse	5'-CCAACCCACCCCTTCAAC-3'		52
	Sequence	Forward primer		
MINT1	Forward	5'-AAGAGAGGGTTGGAGAGTAG-3'	62	53
	Reverse	5'-CCCCTAAAAAAAATCAAAAATC-3'		54
	Sequence	5'-GGGTTGGAGAGTAGGGGAGTT-3'		55
MINT2	Forward	5'-YGTTATGATTTTTTTGTTTAGTTAAT-3'	60, 58, 56, 54**	56
	Reverse	5'-TACACCAACTACCCAACCTACCTC-3'		
	Sequence	5'-ACTTCCATTAAAAACAACACTAC-3'		57
MINT31	Forward	5'-TTTATTTATATAATTTTGTGTATGG-3'	58	58
	Reverse	5'-CACCCCTCACTTTACTAAAAC-3'		59
	Sequence	Reverse primer		
MINT32	Forward	5'-TTTGGGAGGTAAATTYGTTGATT-3'	58, 56, 54, 52***	60
	Reverse	5'-ACCRAACAAAAAACCTAAAAAAC-3'		61
	Sequence	Forward primer		

\* 55 (5 cycles), 53 (5 cycles), 51 (5 cycles), 49 (26 cycles)

5 \*\* 60 (3 cycles), 58 (4 cycles), 56 (5 cycles), 54 (26 cycles)

\*\*\* 58 (3 cycles), 56 (4 cycles), 54 (5 cycles), 52 (26 cycles)

**TABLE 3B-PRIMER SEQUENCES FOR MSP**

Clone	Orientation & Methylation	Sequence	Annealing Temp.	SEQ ID NO:
P16	Unmethylated	F 5'-TTATTAGAGGGTGGGGTGGATTGT-3'	60	62
		R 5'-CAACCCCAAACCCACAACCATAA-3'		
	Methylated	F 5'-TTATTAGAGGGTGGGGCGGATCGC-3'	65	63
		R 5'-GACCCCGAACC CGGACCCCTAA-3'		
RARβ	Unmethylated	F 5'-AGGATTGGGATGTTGAGAATG-3'	58	64
		R 5'-TTACAAAAAACCTTCCAAATACA-3'		
	Methylated	F 5'-GGATTGGGATGTCGAGAAC-3'	64	65
		R 5'-TACAAAAAACCTTCCGAATACG-3'		
CACNA1G	Unmethylated	F 5'-GTTTTTTTTTGGATTTTTGTTTTTGT-3'	60	66
		R 5'-TTTATTCCAACCTTCTCACTTCA-3'		
	Methylated	F 5'-GTTTTTTCGGGCGGTTTC-3'	62	67
		R 5'-TTCCGACTTCTTCGCTTCG-3'		
TIMP-3	Unmethylated	F 5'-TTTTGTTTTGTTATTTTTGTTTTTGGTTTT-3'	59	68
		R 5'-CCCCCAAACCCACCTCA-3'		
	Methylated	F 5'-CGTTTCGTTATTTTTGTTTTTCGTTTTTC-3'	59	69
		R 5'-CCGAAAACCCCGCCTCG-3'		
THBS1	Unmethylated	F 5'-GTTTGGTTGTTGTTTATTGGTTG-3'	62	70
		R 5'-CCTAACTCACAACCAACTCA-3'		71
	Methylated	F 5'-TGCGAGCGTTTTTTTAAATGC-3'	62	72
		R 5'-TAAACTCGCAAACCAACTCG-3'		73
HMLH1	Unmethylated	F 5'-TTAATAGGAAGAGTGGATAGTG-3'	56	74
		R 5'-TCTATAAATTACTAAATCTCTTCA-3'		75
	Methylated	F 5'-TTAATAGGAAGAGCGGATAGC-3'	58	76
		R 3'-CTATAAATTACTAAATCTCTTCG-3'		77
E-Cad	Unmethylated	F 5'-TAATTTTAGGTTAGAGGGTTATTGT-3'	53	78
		R 5'-CACAACCAATCAACAACACA-3'		79
	Methylated	F 5'-TTAGGTTAGAGGGTTATCGCGT-3'	57	80
		R 5'-TAACTAAAAATTCACCTACCGAC-3'		81
DAPK	Unmethylated	F 5'-GGAGGATAGTTGGATTGAGTTAATGTT-3'	60	82
		R 5'-CAAATCCCTCCCAAACACCAA-3'		83
	Methylated	F 5'-GGATAGTCGGATCGAGTTAACGTC-3'	60	84
		R 5'-CCCTCCCAAACGCCGA-3'		85
MGMT	Unmethylated	F 5'-TTTGTGTTTTGATGTTTGTAGGTTTTGT-3'	59	86
		R 5'-AACTCCACACTCTTCCAAAAACAAAACA-3'		87
	Methylated	F 5'-TTTCGACGTTTCGTACCTTTTCGC-3'	59	88
		R 5'-GCACTCTTCCGAAAACGAAACG-3'		89
MINT1	Unmethylated	F 5'-GGGGTTGAGGTTTTTGTAGT-3'	64	90
		R 5'-TTCACAACCTCAAATCTACTTCA-3'		91
	Methylated	F 5'-GGGTTGAGGTTTTTGTAGC-3'	64	92
		R 5'-CTACTTCGCCTAACCTAACG-3'		93
MINT2	Unmethylated	F 5'-GGTGTGTAAATGTAAATAATTG-3'	58	94
		R 5'-AAAAAAAACACCTAAACTCA-3'		95
	Methylated	F 5'-AATCGAATTTGTCGTCGTTTC-3'	60	96
		R 5'-AAATAAATAAATAAAAAAACGCG-3'		97
MINT31	Unmethylated	F 5'-GAATTGAGATGATTTTAATTTTTGT-3'	64	98
		R 5'-CTAAAACCATCACCCCTAAACA-3'		99
	Methylated	F 5'-TTGAGACGATTTTAATTTTTGC-3'	62	100
		R 5'-AAAACCATCACCCCTAACG-3'		101

MINT32	Unmethylated	F	5'-GAGTGGTTAGAGGAATTTAGGT-3'	62	102
		R	5'-CTAAAAAAACAAACAAAACATCCA-3'		103
	Methylated	F	5'-GTGGTTAGAGGAATTTAGGC-3'	64	104
		R	5'-AAAACGAACGAAACGTCCG-3'		105

What is claimed is:

1. An isolated nucleic acid molecule selected from SEQ ID NO:1-42, and regulatory sequences associated therewith.
- 5 2. The nucleic acid molecule of claim 1, wherein said associated regulatory sequences contain CpG-rich regions.
3. The nucleic acid molecule of claim 2, wherein the state of methylation of the CpG-rich regions is determinative of the presence of a cellular proliferative  
10 disorder in a subject from which the nucleic acid molecule is isolated.
4. The nucleic acid molecule of claim 2, wherein hypermethylation of said CpG islands is indicative of the presence of a cellular proliferative disorder in a subject from which said nucleic acid is isolated.
- 15 5. The nucleic acid molecule of claim 1, wherein the molecule is selected from SEQ ID NO:39-42.
6. A substantially purified polypeptide encoded by a polynucleotide selected  
20 from SEQ ID NO:39-42.

7. A method for detecting a cellular proliferative disorder in a subject comprising:
- a) contacting a nucleic acid-containing specimen from the subject with an agent that provides a determination of the methylation state of at least one gene or associated regulatory region of the gene selected from MICP1-42 of Table 1 and combinations thereof; and
  - b) identifying aberrant methylation of regions of the gene or regulatory region, wherein aberrant methylation is identified as being different when compared to the same regions of the gene or associated regulatory region in a subject not having said cellular proliferative, thereby detecting a cellular proliferative disorder in the subject.
8. The method of claim 7, wherein the regions of said gene are contained within CpG rich regions.
9. The method of claim 7, wherein the gene is SEQ ID NO:39, 40, 41 or 42.
10. The method of claim 7, wherein aberrant methylation comprises hypermethylation when compared to the same regions of the gene or associated regulatory regions in a subject not having the cellular proliferative disorder.
11. The method of claim 10, wherein the regions comprise regulatory regions of the gene.
12. The method of claim 7, wherein the agent is a pair of primers that hybridize with a target sequence in the gene or associated regulatory region of the gene.
13. The method of claim 7, wherein the nucleic acid-containing specimen comprises a tissue selected from the group consisting of brain, colon, urogenital, lung, renal, prostate, pancreas, liver, esophagus, stomach, hematopoietic, breast, thymus, testis, ovarian, and uterine.


14. The method of claim 7, wherein the nucleic acid-containing specimen is selected from the group consisting of serum, urine, saliva, blood, duodenal fluid, pancreatic fluid, cerebrospinal fluid, pleural fluid, ascites fluid, sputum, stool, and biopsy sample.
15. The method of claim 11, wherein said cellular proliferative disorder is selected from the group consisting of low grade astrocytoma, anaplastic astrocytoma, glioblastoma, medulloblastoma, gastric cancer, colorectal cancer, colorectal adenoma, acute myelogenous leukemia, lung cancer, renal cancer, leukemia, breast cancer, prostate cancer, endometrial cancer and neuroblastoma.
16. A kit useful for the detection of a cellular proliferative disorder in a subject comprising:
- a) carrier means compartmentalized to receive a sample therein;
  - b) one or more containers comprising a first container containing a reagent which modifies unmethylated cytosine and a second container containing primers for amplification of a CpG-containing nucleic acid, wherein the primer hybridizes with a target polynucleotide sequence having the sequence selected from SEQ ID NO:1-42.
17. The kit of claim 16, further comprising a third container containing a methylation sensitive restriction endonuclease.
18. The kit of claim 16, wherein said modifying reagent is bisulfite.
19. The kit of claim 16, wherein the primer hybridizes with a target polynucleotide sequence having a sequence as set forth in SEQ ID NO:39, 40, 41 or 42.



20. Isolated oligonucleotide primer(s) for detection of a methylated CpG-containing nucleic acid wherein the primer hybridizes with a target polynucleotide sequence having the sequence selected from the group consisting of SEQ ID NO:1-42.
- 5 21. Isolated oligonucleotide primer pairs selected from SEQ ID NO:43-105.


1/14

FIGURE 1



2/14

FIGURE 2




3/14

FIGURE 3




4/14

FIGURE 4



5/14

FIGURE 5



6/14

**FIGURE 6a****PL3-17, CSX, MINT23 MICP1 (SEQ ID NO:1)**

ccccggcgccccggccctggctcgcggaatggcgccagatctcaggccctgcgtgcccagctcagtcaccagttccaaccgggg  
gtgcccattgactctcggagggcactcctggggggacagctaagacaccaggctgcaggatcactcattgcacgctgcataatcgcc  
gccacaaactctcccgctgcgcaagaacaaacgcgcgtgggacagaaaaagtcttaggtctccgcaggagtgaatgcaaaatccag  
gggactcagggtcatgttgggagcccccttccccccgagagtcaggagctgttgagggtgggatcggtgagggtcgcgccacgcg  
ggtcccttcctaccaggctcggataccatgcagcgtggacactcccagttgctctcggaatcccggg

**PI8-13 cyclinG micp2 (SEQ ID NO:2)**

Cccggggagggtggttaccgctgaggagctgcagtcctgtcaaggtagtgggactgcgcgagagttgaccgccagtgccgggtg  
gggagctgggttggggcgccggggcgaggagtaggtctggcccgccctttccacactaaactctaccgctgttgtgagcacaag  
cccaggctagtcaggagctggaggggcgaggcgatccggcctcctgaggtgcctttcgtgtctgccgacccagtcaccagggacta  
gcctggggaggaagaatggaacccctgcagttagaggttcctcacatgactagctctgaagacctcctgccttctgtcttttagttggtg  
gggagggaccttccatgtatccagggttagcttgtgccggg

**PL-3-12 MICP3 (298 bp, ECEL-1)(SEQ ID NO:3)**

Cccggggagagctgatccggacaggggttccgaggagtaaaaggaagctccctggtgaaggtagctctgcgcaggcgctgtgc  
gggcagcccaggcactccgtcagcgccctctcaatccttaggaggagtcctccctgggtggtgctccagggtgtgggctggacct  
gacggccccagctgcgtagctccagctcctttcaaccgggttggtggcggttccagtgaggacacgggatcgagggggactcct  
ccgggtgtacccgctaccctcactagtcgccgggatgcg

**PI3-9 309bp, micp4 gad1 AC007405 (SEQ ID NO:4)**

Cccgggacagagagattgcgggctaattcgggtagatcgaggaccccacagagaaggggcccaccggccatcgctccacaccctc  
cctccgacctcactctagccccgcgcgcagtcgcacagcaactcgggcagcgggtcgactacggcccctggaaaagtaacag  
gttaccgttcttagtagcgccttcgggtgctgctgccagggcgccctttggagggacaggcgctcgcagcatggaagctcaaggga  
aatcgctcttgcctcactcaactagagcctcagcctccgtgcttccccggg

**PL3-18, 2<sup>nd</sup>, ICAM-5 (630 bp, MICP5)(SEQ ID NO:5)**

Cccgggagcatcggggcaacttaccgctgcgaagccaccaaccctcggggctctgcggccaaaaatgtggccgtcacgggtggaatg  
tgatagggggcaccgcggagttaggcaggatctgtgggacaacccggctggacttctggccccgtgtgagccctgcaatcctg  
tttccagatggccccaggtttgaggagccgagctgccccagcaattggacatgggtggaaggatctgggcgcctgttttctgtgagg  
tcgatgggaagccacagccaagcgtgaagtgcgtgggtccgggggcaccactgaggggggtgctgctgccgctggcacccccaga  
ccctagtcacagagctcccagaatccctagagtcctggcaccgggtatctacgtctgcaacgccaccaaccggcctccgtggc  
caaaacagtcgtcgtgagcgcggagtgtagcgaggccaggcggttagggagcagggtgccccacgggtccaggcactccctga  
catccccatggctgtttgcagcgccaccggagatggatgaatctacctgcccaagtcaccagacgtggctggaaggggctgaggct  
tccgctgctggcctgcgccgggg

**PI8-9 308bp, micp6 AF132611 MCT3 (SEQ ID NO:6)**

Cccgggtggtgacctgacctgcccacaggccccgtgtccagatcctcgtgacctgttggctgtgcccgggtgatgctggcggg  
tgggtgctgggttccgcgggcatgatcctagcttcttggcacgccttctggagctctacctgaccgctgggtgctcacagtgta  
gggccccctggtctcctcctccgtgggttgggggtcgggggttctgctgcaagatctgctcctggttccctataggggacagtctcg  
aagtcctcgggtgggttcccggaatctgctgggttccccggg

7/14

**FIGURE 6b**

P18-17 548bp, micp7 pax5 (SEQ ID NO:7)

Cccgggaatccacagccacatttccgattgtggcgaaatctgctcagtggtctgcgatgtccagttgccgccggggggccccctttcc  
tcgagctctaggctcttccccctaggttgcgacccagcctcgtgaccacccccctcaaaaaaacaacaacacitcttctgaggacgat  
tcactctccaaaactgcattgtccggcgggcccaggagctctctacggacgcgtcccgcctgagacttccctcgagccacccgctgcagg  
cccacggcttcagtggttaggcccagcagctgaaccaactcaaggctgggggggaacaggaggaggcttgagtctggcccgaag  
agagagggtggacatgccacacctctgctcggctctgttgatctgatttctctctggaatcaagtcctggggctctgggactccaca  
acgtctcagggctcgagggaatgcgattccacttacggcgccgggtaaggtgtctggaactcccaccaatctcagaaactactgag  
atgttctgctctgccggg

P13-50 255bp, micp8 ppENK (SEQ ID NO:8)

Cccgggaaccgcgaggcgatctgagtcgcctccacgtctacctaaaagctgtcgccggggaggggcgggggccccagaaaggagca  
ttctcggggtctttgtcgcagatccccctgctgaggctgtcgccggcgagggtctgccgagggaacccgttctgcgccaggcagg  
ctcgaagcacgcgtccctctctctcgcagtcctatggcgcggttctgacacttgcacttggctgctgttgctcgggccccggg

P13-3 431 bp, MICP9 (SEQ ID NO:9)

Cccgggcagagctcggagcgcctccatccccggaaccaggggactccctggagtgtccgggtccaggctacgatcgaggcgccc  
ccatcccttggggccaggagaggatcgagacaccaggaggccctcggggctgggtgaagatcttgggtccgggggtccggga  
gaggatccacccctcccaatccccgactcccagggtctgaccaagaatggaggtgcccccttctccaggcctcgagccctctgagcg  
ccgaggccggccgcctacaggtcccccgccgctggcgacccctctattcggttccctcacgtcacccgctgtccggcgccctggga  
actgggtccttgaatttctctctctggggctgacagatggccctctttcttctctgcggcagcctcgccatcccgggtcccggg

PL3-14 MICP10 (600bp) (SEQ ID NO:10)

Cccggggacggggaggaggagggtgcccggatgtgaaccgggggaaggcagctggggctggagagcagcgcggaaggg  
ggcccaggagcttgaaagaggggccaagaggagggaaggaaggtggcgggcgacggggagaggaaagaaaaagggtgtctt  
ggcggtggccttggaagagaaaggggcaagggtataattgacaaggcactgaaagtattgaagtcagagccttgggaaggatcta  
ccgaactctcggcggtccacgcggggacagacctcagcccgtgagccttgagctccacgcggggacagacctcagcccgtgagcc  
ttgagctccacgcggggacagacctcagcccgtgagccttgagctccacgcggggacagacctcagcccgtgagccttgagctcca  
cgcggggacagacctcagcccgtgagccttgagctccacgcggggacagacctcagcccgtgagccttgagcccagaaggagtgg  
cagcctcaggacgttggcaggtggcctggaatgtgagggaagcctcagccccgccaggaacagagctggcgctgagtlcccggt  
cgccccggg

PL3-23 359 bp, MICP11(SEQ ID NO:11)

Cccggggcgacgggcgtgagggtgggtctcatcgcagggcgccgggagcctccccgctccgctagctcaaccaaggaccg  
ctcagagggtctcaccctgaacctcggttttctaaaggagcgagaccagattcccttctctctcagctcgtttgggttttctcgttct  
tttgcactgagcacggcaatgcgcagacgtcagctctcactgctcatccgatctgtaacctgaggtgagcccgaagaccgtgc  
cgccggcgggccacccagcgcggtccgctgaggatggaacagcaagtgcgcgccggccaggccgccacctctccctctcca  
acagccccggg



8/14

**FIGURE 6c**

PL3-25 370bp, MICP12(SEQ ID NO:12)

Cccgggaggtagcgggagattgcacacgcgatcctgcgagttccgaactttggaagatcgtgacccggagagacccttgggagga  
gagggccggccacctcctaggggtgctgtttttaagggtcaaccaggacgctacgggaagcacctggcgcatccttgaacagtg  
ggcttggtagccacccgcaacgcctggcgggaaggaaatggcggggcatcgtgtgcctaattgaccccgtcacagaccgccccaa  
tccgaggggaggatgagctcagaggacctgccaggacgctccttccactttccaggaaaaccgacggcgtgcgcgctccgtgt  
cctcgcggagctgggggtccccggg

PL3-32 324bp, MICP13(SEQ ID NO:13)

Cccgggcctgggctgtgccagcccgccctgccagtctcgccccattctctgacggagggatgcggcgccctggggcctcgaagc  
tccggcggttttgagaagttgaagctcagccgcgatgatactccacggcgggcggggatggtgaaaggggttgtagccacctgc  
tgctcagactgaagtgcgactccgcgttcagaggcgtcgggctgctgaacaccgggagctactacgagcacgtgaaggtgagctgct  
tgcgccctcccgccgagccccgctgctcgccctccgcaatccgcagtcctaccttccccggg

P13-49 392bp micp14(SEQ ID NO:14)

Cccgggaaagacctegagagaccttctcaacacgtctccaggccagattcccctaccatggctcgggagcaatgacgcgctcccc  
tcgccactegcatggagaccgacttccctggcgccccacgagaggctcactgacctcgccgtctacctcgtgagagaccgcacct  
gggcgcgctcgagacacccgagattcccgtcaccgagagcttgaggccttcgtctcctgcatggcctagagaccaatctcgcgacct  
gtctccaaacgcctcaggaggcttgactcccttgagtcggccagtgagctccaagagatacccgctcgcgattcgagagcagagcg  
gggttcttgcctccactcgagatgaatgcctgtctccccggg

P18-1 358bp, micp15 AP000913.2(SEQ ID NO:15)

Cccgggagaggcgacagcctcatcegtttatttctcccttgaccattgttcagegacttccccctcgttcagcatccaggttccttacg  
gctacagtgcgccagccccgcctcaccagcgcgacatttgccttgccctaccactcagacacagtgcccttttcggttcttcaacttg  
ctaagcgttttctatcgatatctgcaggtaacagatggcacgctctcaaatagggtaatcgaggagggtctaataaaggaactatttc  
aacagcggagtaggcgttagggactccagtaggagtagggctgtgtcccaggatactaacagcaggggcgccctggccgccccggg

P18-5 545bp, micp16(SEQ ID NO:16)

Cccgggctgtgcggagatgcgcaggcttggggcgggcttcaggagggaactgggaaaggatcgtgccctagggtctcctggtgcg  
aaaggggtgcggcgagcaggtgggatcagggtgaggtccgctggcatttatgggggtgggtggtggaaaattggaaagagttccgg  
ggagttgtggaagactccggaagaagggtctgttgaaaggcgggtgtgtgaaaggatgtagggggaatgacagaggggtgttttaggg  
gtccaattgggtgaggtctgggggggaagatcagagagggtcatggggccaggagtgcacgtctaggagttgatgggtaggcct  
gaggggtcggagaagggtgcggctggggaggagtctcgcgattgagttgtcggggcgggcggggaagctgacagctgcctctgtgtg  
ctcaggaggcgactccgccggtgcagccgccccgacgcgggaggaccgggcctcatcgtccgggagcgctccgcgtcgcga  
ggccgcggcgccgcgcgctcctcatccccggg

9/14

**FIGURE 6d**

PL3-16 MICP 17(510 bp, MINT 20) (SEQ ID NO:17)

Cccggggggcgctgaggttccttctcaggcggaggaggcgaaccctgtagcccacaacgccgggcttcgattttgaggagcttc  
ttccgggatgtcgctatactggccggagacgggccttgcgtgtccattgggggatggcgatggggaccagtttccgggtagagaagg  
agataactcgatacaggaacgcacaggcagcctgaaagcagcccaggatctcgacaggggaagggaagaccctgtccctttgcc  
aaatcctcccgccctgtccttgccttctgtcccagatcccaagccctcgtacctgcactcgggactcggtcagcccgatacgcagtgc  
cagtcctcacgcataaagatgtcggggtagtgagcttggcgaagctcctcctaactcgttgagctgtgcgggggtgaagcgcgtc  
cggtggcgcttctgcttctgttggccctgctgctggccggcttggctgggggtcgggccgccctggggcccggg

PL3-8 386bp, micp18 AC005998(SEQ ID NO:18)

cccggaacagttcaggacgctcaagaccagaagcgggagcaaaccacaaaggagctccaaggaggtgtgtgtggggagagcc  
agggggacgcaggactaggctcttctcgtcgcaaggggtggggaaacccgcgaaagccaggagtcgcgcgactcacgccctc  
gcgccaccaggcagagccaccgctgcaaggagcccacgggtgcgcgctcgtccagggcggatcttccacacccccctaccct  
caaaagctcaggctggagcggatcatcagtgccgactccggcacccccaccacccagcaggggttaaggaggaggtggcgccact  
cttgctlacagctcctgcgcagggtccagccgccaatcttccggg

PL3-33 514bp, micp19(SEQ ID NO:19)

Cccgggctgaatggtagacgttctggcgccgggcagcggccaccggctggttcccacttcgcgcgcacccctaaactgtgttcta  
gaggccccagcctcgccttgcagcgcctcactagctcctgaggactagggactcggcggtgaggcgggttggcggtcgaacgag  
ctggcgctcttcttctctcgtcgctggctggctcagctggccctccacagctcggagcaaggccatagcagggagtggaggtat  
attgggctgtcacctccttgcgtggccggagttattttagactacagactcgggaagaacagacgcgccacgctcgttggcattgcttc  
ggatcgcagctcctccttgggggtgccccagcttggcggttatttgcctgcgccaggctcggcnacggtcaccggggccagcggggag  
ggacggacggcaggtgaccagcctctgctgtgaagaaattctgcgcgcccggagctgtccctaattgcattcccg

PL3-51 279bp, micp20(SEQ ID NO:20)

Ccggggatcgggagcttggagtgagngctcggcgtgacctgtaggagccccgcgggtagagcggcgctgccccttcgctccg  
gggtgaactgaaacttctaggggagagggtcggcgccagcctcgcggggttcggagaagaccagcgtgtgcagggtcgggg  
ccgggcagggcagagcaggggtgaaaggagagacctgtaatgacggcggaattgggggtcggagggttcgaggggaggggccc  
gcaacctgaacaattgcattcccg

PL8-21 422bp, micp21(SEQ ID NO:21)

Cccgggtctggcttggctcgtcccgccagatcccgttcaaactcagctgccaccaagtgcgccttttctcttgattgcgattctgca  
cgaattttcagttgagggtggttcggcgctcagccagccttgcctcgaagacgcggccttggcttaggaaccttcaggtgggtgtt  
ggcgagtgcccttagttccctagaattcgtttgcctcccgccctcagccgcgtggtcagcagctcgcgagaacgcagctgg  
gcagtcgggacggctcgtggcgcttctaggagcagtcgaaagggttcgaggagctgccagggtccttcccttaggttccac  
actggatggccgtaactcagtcgttgacggcgacagccaggccctgatggactgtcaggtcccg

10/14

**FIGURE 6e**

PI3-18-2 mint32, 464bp, micp22(SEQ ID NO:22)

Cccgggtacctgcacagctcgtccctcccatccttcgggtcttcgctcgaacgtccgctcctcggtagggccttccctggacaacgca  
tttgaaacgtaaccccaaggcaagaagccacctccaggcgcgcagccgaagccagtgccaaggaggccggagactcgggtgcc  
cgcgcaccccgaacacagcctctgaggggtcctctgagcatccttcagcgtgtttgggaggcaaaactcgttgactagctcttgagagg  
agtggctagaggaatccaggcggggaaggggacggtggactccaggagagtgtaatttacaaaggcggggggcggggacgcca  
ggtccgagtgccaggactctgcgccggacgttcgcccgcctttcagggtccctgcccggctcctgtacccgcgcgggtccggaga  
acctctgagcaccggccccagccccggg

PI3-4 257bp, micp 23(SEQ ID NO:23)

Cccgggatcgggtgcccgttagtgggcacaggacgccgggtgtccgaagggtgcctggagatgcaactgaccttggcgggcatca  
gaatgacgagtggcagcagcaggagcggggtgacgaacaagatcacgaaggacttgaacttggagacatagctcagcgccgagg  
ccatcgcggggaggagactggcgggcgagacgagtgggggcagctagaggcgcgcgggcttaagaaggggccacagtc  
cccggg

PI3-5 350bp, micp24(SEQ ID NO:24)

Cccggggatggcgcgccaggttaaggcaggcggacgcgcggacccctcggcgagtgccggccccgaaggcggtagggcgaga  
aagagctgggaccccccgcaacttcgggatcgggtgggtgaggctgggcaggcctgatgctcaggggttcgtgccgggaagtca  
ggctctcgacaacctctctccagctctccgccgccgtacccacggccagctccacctggggaaaccccttggcgtggctgttt  
cgttacaagttatcctggtagagtgggcatgaaggcctcggaggcagtgagtaaacttcatacttctgttcttgggtgaatcctggatccc  
ggg

PI3-6 337bp, micp25(SEQ ID NO:25)

Cccggggtgccgggtggagcccgagattcgtcgcgacgactgccccctgggtatccagcgccgaaagtccccctccgag  
ctgcaaggctcctccctgggtcgcgcgggacagattttctccttcttggtacacgcctaacagagaagctatcccgagggacctca  
agaagtcccccaagccgtactcaaaagcctttctccctcctcctcaagcgctcacttcccaaaggaggaccccgacccctgactgcct  
gagccaggtccccagcatggtccgcaacccctctcgactccggcatccacctccagggtgacgtctacccggg

PL3-11 MICP26 (229 bp) (SEQ ID NO:26)

Cccgggggaaagagatgagtggaaatcgtgggccggacctgcaaggagagactcggcgggcaccttgccttggtctgaggtcgtct  
gcaggaagcggacttttctcctggctcaggatgggaaagacaggggatgcctgaagtcaacggggacttctgttccatctctgccccgt  
tctccaggcccagttttcctgctttggttagattttcaacgtatccggg

11/14

**FIGURE 6f**

PL3-13 MICP27 (427 bp) (SEQ ID NO:27)

Cccggggctgctgaccgagccccagggcagccccgcccttccccctcctgaagcccgacgtcttctcatggctccgtctaccggcttc  
ggagaccgctggacttttcgccgctccggaaccctatatgaggaagcaaatacgcgtccgccacagcctccaactaggaaactccg  
cgactctcagccccctcagaagagaaacggagacgcgccaagcaaagccgttacacggactgtgcacgcgctccgggtgtccctgcg  
cgtgacacaaatttggccccgagggagctccatgtgcctgagtcaggagccctagatgccagcgacagcttgcaccaggcctgc  
gacgccaatggggcgggagtcggcggagctcaggacactgacgacgggcctgggggaaagcgggtccccacacagccccggg

PL3-19 (470 bp, MICP28) (SEQ ID NO:28)

Cccggggacagggggacccccagatgctgcacggctgacaggccaacgtggcagaagctccagcttcacaggaagccagtgacc  
atgagagtctgtagctgtaacgaagccacagagctgtggctttcttcccccttcagctctaggaaagggtatctgccctgcacagatctcc  
ggaggcctggctgggctctgagagcatcagactgattatcgtaaagaaataatctctgcagacacattccttctagaagcaggggaca  
aagcccagcttcaaagacaattccacacacgccctccctgccctgcacagctgcctgccgggtgggagcagagcccttgcagccgg  
gctcaggggctgggcagggacagcgtgtggcaggggcacagctgagacaggagcctcaaagcgacaccaacccgacgtgaag  
ctacagttgaggagacacagctgccccattccccggg

P13-20 (bp 264, MICP29) (SEQ ID NO:29)

Cccggggcggcggccggattgcgggtgggtgagaggcagcagacgccgtgtttacagctctctcgctagtccacctcagccgcg  
gtcttagggctgagccagtcgcctccttcttaagattctgttcacagcaggggctgggtttctaaggcaggtttctaagggtgtcttctac  
agacaccgctgctgtaccttgcaccttcagcgtgggcacagccaggggcagcgcgagagggaggcaacgagaggggttcccgg  
g

P13-21 (bp 371, micp30) (SEQ ID NO:30)

cccgggaccccaatgccaggggaggggcctgcaggacccccagcgggtgggcgagttgtgtcctgggtcaccttgtgttgcagcgtg  
gcgggtggcaggagcccagcgcgggaggacattttcatagcctcctacagtgagaaacgccccccacccgacgctgcgctcatctgtg  
tccccgtgttgcggggctctggtatccacttgcgcgccctatgtggtggggatccaccagagcccagcgtcaagttatacgggcg  
cttcactcagcgtcagccaagaccaggaagcgttcttgcggttaggagacgtctgcaagagataaaaagctagcccacgatccac  
ccacaatcctcgtgtccccggg

PL3-22 bp 179, MICP31(SEQ ID NO:31)

Cccgggaactcgcggcacccactgggtattgtcgggacccagcaagtctaggaacgggggtgggtagagcatccttcgggcactg  
ccgttcgtcccaaaaagaagaccaccgcgggtcccaggggccacggcgaggacgggcactggtcagattccggacaggcggctct  
ggccccggg

12/14

**FIGURE 6g**

PL3-34 445bp, micp32(SEQ ID NO:32)

Cccgggctgtgaccagcgaattcgggccccgcaggtgcagctgataggagaaatccggctccgggagcgaaccagcggcgga  
aggcgggctccgcgccagggcggccttgactgcaagaaggcgaggatgcgcgcgtacttcgtgtccttgggtcatcgtcacgtg  
tgagtatcgaccaggtcatcatcgacgtgggtaccatagtggagtagttggcaactcgttagagtctgctggaggaacgagcccg  
cgtaggacggacacacctgagtccccctccacgcgagccaaagcgggtgcagggcacctcccaccacatttctggccaaagt  
ccatttgaggccccgccctctcctctgcgcagcttagagactggcgaggcacgcgcaaacgccctcttcctgagacctgaccccac  
caccacccggg

PI8-2 357bp micp33 AC002133(SEQ ID NO:33)

Cccgggggagccccggaccccgcatccccagggcgcggaaactggcgaggccccaggagctccatttatagctcagttccac  
tgagcgcagtcctcttaggacctgggctgagcaagtttctccactctctccctcctcctcacccttgctgcccccaaccccg  
gcagggcgcaggtgtcaaccagccgggacccccctcctcctgaaccaggtgtccggctccagaccccaattgagctgggg  
gcgcccaccgcccgggggatcccgccctgcgtccccattcatccgcgtctcagccgcgggagtttctcaacgggaagaggcgga  
gtcccg

PI8-3 312bp, micp34 AC005826(SEQ ID NO:34)

Cccgggaggagagttggggcttgggggacgccgtgaactccatgggtcccagcacgcggtcctggccaggagcggggctcgcg  
aactgccgtccagattcccaaggagacaaagacccgaaacacagctcaaagttccgagagcagtcacagcggggccaggagc  
tccagaagtgtcagctccaacgactccagagctgcacactggcctctattccccaccgcaaagccccagagccgcagagacttcaa  
ggcagccggagaggagagggccccaccgagcactacggcgggtgcgcacgccccggg

PI8-6 372bp, micp35(SEQ ID NO:35)

Cccgggagcgggctcgttggggcgccaggccacgctctctcattaacatcccgctcccggtggcgaggggagccggccaaagt  
tcctcgcaaagtggcgagcgaaggagcgtgagcactgaegtctgggctggggaggagcgggtccgagcaggagcggagaggg  
gacagagggaaaggagggcgggtgtcttctcaggaatttgagctggggatctgcatcctggccattgcagtcctttagcatcctcgc  
gcccctgagcgcgtggaggctgcaggctgcgccctccagggtgatgcgcgtcctgctccgcgttctgggacgtcgggga  
caaaagtggaggagacgggagagcccg

PI8-7 399bp, micp36 AF132611(SEQ ID NO:36)

Cccgggctgcgagcgcggctcctggattccagcctcccgccctccaggcgtggaatggacacggacgccacagtggcgggc  
caggtagtccggagtcgggggcccaggccgcggcgccccgcgcctcatcacttaccttgcccttagctatcaattccatgatgtagcc  
aaattcactcatctccccagactccgacatgtttacaccccttcacaaactctggaggaccgacgcgggtgtatcgaatttgcctttcttt  
ctcttttctgttttagtctgagttttgcccagctccccgccataagctgttaaccaggaaaagagggggaagcgccggggaaagcaag  
aagcgggcttgggtgaaatgaaggccatcgagggtccccgg

13/14

**FIGURE 6h**

PL3-31 307 bp, MICP37(SEQ ID NO:37)

Cccggggcccggtgcgaccggtgccgacttggcagccgccctgtgcgctcgacgaaagggtgagaaggaggcaggagtgcagg  
cggaaggagtgggcaatcagcggcggggacgagagtgtgtcttcggggaaaccaagtctgagtgcgctgaaggggagtgtgcg  
gagcgtgccgtgcaccccgagcccccgccctcattgcctctcgcctctctccacctgccccatgatctgcgccagggaccggtcctct  
cccgctccgaggtgtctaggtggccgttctggttgcctgggacccccggg

Pl3-37 331bp, micp38(SEQ ID NO:38)

Cccggggccacctctgaggcatgaaccagagacgcgcgccctgggtctgggaaagcaggaccgctgcgccagcgcctcaggg  
gtagaggcgggaaacaggccccgcggtcgctttgctggcgggcggaaggcgatctgacgatcaggaggagttgcgccctctcttgg  
gcctcgtgaaggaaacaagagcaattacagcgtggcgccggccacgtagtccctggggctaggtgggccaatgctccgggcccggg  
ggctggagcgcggaggctggagaggaggaggaccctccgcggctccaggtctcccagctggagggtcacgccccggg

Pl3-43 304bp, micp39(SEQ ID NO:39)

Ccggggcccggtgcgaccggtgccgacttggcagccgccctgtgcgctcgacgaaagggtgagaaggaggcaggagtgcaggc  
ggaaggagtgggcaatcagcggcggggacgagagtgtgtcttcggggaaaccaagtctgagtgcgctgaaggggagtgtgcgga  
gccgtgccgtgcaccccgagcccccgccctcattgcctctcgcctctctccacctgccccatgatctgcgccagggagccggtcctct  
cccgctccgagctgtctaggtggccgttctggttgcctgggccccggg

Pl3-44 307bp, micp40(SEQ ID NO:40)

Ccgggggtcccagcaaaccagaacggccacctagacagcctgcggacgggagaggaccggttccttggcgcatcatggggc  
aggtggagagaggcgagaggcaatgaggcgggggggctcggggtgcacggcacgctccgcacactccctccagcgtcactca  
gacttgggttccccgaagacacactctcgtccccgccgctgattgcccactccttcgcctgcactccagcctccttctcacccttctc  
gagcgcacaggcgggtgccaagtcggcaccggtgcgaccggccccggg

MICP41 also known as PL-3-2, 43(SEQ ID NO:41)

Ccggggcccggtgcgaccggtgccgacttggcagccgccctgtgcgctcgacgaaagggtgagaaggaggcaggagtgcaggc  
ggaaggagtgggcaatcagcggcggggacgagagtgtgtcttcggggaaaccaagtctgagtgcgctgaaggggagtgtgcgga  
gccgtgccgtgcaccccgagcccccgccctcattgcctctcgcctctctccacctgccccatgatctgcgccagggagccggtcctct  
cccgctccgagctgtctaggtggccgttctggttgcctgggccccggg

14/14

**FIGURE 6i**

P18-19 479bp, micp42 3' of FLJ00083(SEQ ID NO:42)

Cccgggttcctggcttgaacctgtttctccctgttctgccaggcatgctggtcggaagggtgtgtngctgtnngcttaggtgggtg  
cagcccgctccacgtcacggcgagctctgtttcctgggctggggacagtgaggctacgctgcccacctggagctctggctccttcg  
ggtacctgttccctctcccagagagacccccagctgcatgcaggcctagtgggctccacggcgagctggttcccaggctacctgggt  
tgccacctctgtgggtcccggtgccctctcgcagccgctacttccctaccctcttggccctgcattccacgtctcatggagcaa  
cgagagcagggggttgagccctgtggaaatctggggaggcactgcttctccctccatgtgagcagcttcaccagcctggggtcag  
tgcttacgctccacgcggcctggccttccccggg

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US02/05681

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) :C12Q 1/68

US CL :435/6

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

USPAT, PGPUB, DERWENT WPI, BIOSIS, MEDLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A,P	US 6,251,594 B1 (GONZALGO et al.) 26 June 2001.	7,8,10-15
A	US 5,871,917 A (DUFFY) 16 February 1999.	7,8,10-15
A	US 5,856,094 A (SIDRANSKY et al.) 05 January 1999.	7,8,10-15
A	US 5,756,668 A (BAYLIN et al.) 26 May 1998.	7,8,10-15
A	US 5,552,277 A (NELSON et al.) 03 September 1996.	7,8,10-15



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"G" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

23 MAY 2002

Date of mailing of the international search report

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

KENNETH R. HORLICK

Telephone No. (703) 308-0196



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US02/05681

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☒ Claims Nos.: 1-6, 9, and 16-21  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
  
these claims contain SEQ ID NOs which cannot be searched as no Sequence Listing in Computer Readable Form has been submitted.
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**